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ABSTRACT 
Zhixian Yu: Excess Centrosomes in Endothelial Cells: Causes And Effects 
(Under the direction of Victoria Bautch) 
 
Tumor endothelial cells, which line the interior surface of tumor blood vessels, were 
considered genetically normal until recent findings showed that they can be aneuploid, and have 
compromised p53 signaling and excess centrosomes. However, the causes and effects of 
centrosome over-duplication and compromised p53 signaling in endothelial cells remain elusive. 
In this dissertation, I designed and performed various experiments to investigate these questions. 
I found that some BMP ligands induced BMPR1A-dependent excess centrosomes in primary 
human endothelial cells, likely though SMAD signaling. In addition, hypoxia and abrogated p53 
signaling, but not inflammation, promoted centrosome over-duplication. These results contribute 
to our understanding of tumor microenvironment. I also demonstrated that excess centrosomes 
induced p53-dependent senescence in primary endothelial cells, indicating that the response of 
centrosome over-duplication is dependent on whether cells have intact cell cycle. This is the first 
evidence linking excess centrosomes and senescence, and may also help explain the abnormal 
morphology and function in tumor vasculature. Finally, I showed that loss of p53 induced 
angiogenesis in vitro by promoting endothelial cell migration and proliferation, but not in mouse 
retina vessels. In summary, my thesis work helps understand the causes and effects of 
centrosome over-duplication in endothelial cells, contributing to the studies on tumor 
microenvironment.  
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CHAPTER I-General Introduction 
A. Tumor angiogenesis and tumor endothelial cells 
My thesis work started with the observed abnormalities in tumor endothelial cells (EC), 
and I tested the effects of several tumor environmental factors on EC. This section summarizes 
basic understanding about tumor EC and their environment. 
Blood vessels, whose inner surfaces are lined by endothelial cells (EC), support tissue 
growth by providing oxygen/nutrients and carrying away the metabolic waste. The growth of 
blood vessels can be divided into two consecutive steps: vasculogenesis and angiogenesis [1]. 
During vasculogenesis, embryonic angioblasts differentiate, migrate and coalesce to form a 
primitive vascular network, which is then expanded by angiogenesis to form mature vessels [1,2]. 
As the major method of vessel expanding and growth, angiogenesis is defined as the process that 
new vessels form from pre-existing ones. Upon the stimulation of angiogenic factors, such as 
vascular endothelial growth factor (VEGF-A) [3], some EC in pre-existing vessels respond and 
become tip cells, and begin to migrate towards the stimuli. EC adjacent to tip cells follow the 
migration of tip cells to support sprout elongation [4] [2]. At the final stage, tip cells anastomose 
with cells from neighboring sprouts and build vessel lumens, which allows for blood flow [2].  
Similar to normal tissues, solid tumors, specifically those with a diameter larger than 2 
mm, require blood vessels for their growth [5]. To induce angiogenesis in the tumor 
compartment, tumor cells and tumor stromal cells secrete various angiogenic factors, including 
VEGF-A [6], Interleukin-8 (IL-8) [7,8] and bone morphogenetic protein 2 (BMP-2) [9,10], to 
recruit blood vessels from the surrounding environment. Tumor vasculature is morphologically 
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and functionally distinct from normal vasculature. Tumor vessels appear tortuous and leaky, and 
have irregular blood flow [11]. Therefore although most tumors are highly vascularized, the 
tumor environment does not acquire sufficient blood supply and become hypoxic, leading to a 
more clinically aggressive phenotype [12,13].  
Despite the morphological and functional abnormalities, tumor EC were originally 
considered genetically normal and stable because most tumor vessels are recruited from their 
normal counterparts [14,15]. However, recent studies indicate that tumor EC, similar to tumor 
cells, have genetic abnormalities such as aneuploidy [16,17]. In line with this, ~30% of tumor 
endothelial cells possess excess centrosomes (>2 centrosomes/cell), which can contribute to the 
genetic abnormalities in these cells [17,18]. Previous studies in our lab demonstrated that high 
levels of VEGF-A induce excess centrosomes in EC [19]. However, it is not known whether 
other tumor environmental factors contribute to excess centrosomes in EC. In addition, the 
effects of excess centrosomes on EC cell cycle remain elusive.  
 
B. Centrosomes 
I found that several tumor environmental factors induce excess centrosomes in EC. This 
section summarizes the structure, regulations and common abnormalities of centrosomes.  
Centrosomes are important organelles involved in multiple aspects of cell function. A 
canonical centrosome is comprised of two centrioles and their surrounding pericentriolar 
material (PCM) (Fig. 1.1). A typical human centriole is ~500 nm long and ~250 nm wide, and it 
is has a cylinder structure formed by 9 radially symmetric triplet microtubules [20-22]. At the 
innermost core of the proximal end of a centriole, there is a cartwheel structure containing a 
central hub with 9 emanating spokes connecting with outside microtubules [23,24]. At the distal 
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end of a centriole, there are 9 doublet microtubules, which are modified and associated with 
subdistal and distal appendages [25].  
Over 150 proteins are involved in building the centrosome [21,26]. Sas-6, which can self-
assemble to ring-like structures, exists at the cartwheel core of a centriole, and helps dictate the 
nine-fold symmetry structure [27,28]. Another protein, Sas-5 (or the orthologue protein STIL in 
human), is also present at the cartwheel structure, and cooperates with Sas-6 to assist the 
cartwheel formation [29,30]. Sas-4 (or the human homolog CPAP), is recruited to the central 
cartwheel structure by Sas-6 and Sas-5, and promotes centriolar microtubule polymerization 
[31,32]. Centrioles are surrounded by the PCM containing hundreds of proteins [33], and serve 
as the dominant microtubule organization center in the cell.  
Normally centrosomes are duplicated once and only once in each cell cycle, reminiscent 
of DNA replication. A typical G1 phase cell has 1 newly born centrosome, which has two 
centrioles orienting orthogonally to each other. New procentrioles begin to form near each 
centriole at G1/S phase, and they continue to elongate throughout G2 phase until reaching 
similar size to their mother centrioles. Before mitosis, the fibrous tether between two newly 
formed centrosomes will be severed to allow them to migrate to opposite ends of the cell and to 
set up the mitotic spindle [22]. After cell division, each new daughter cell will inherit one 
centrosome to maintain homeostasis.  
The signaling pathways controlling centrosome duplication are complex and not yet fully 
understood. It is believed that the CDK2/cyclin E complex, which initiates S phase and promotes 
DNA replication [34-36], licenses centrosome duplication [37-39]. The exact mechanism of how 
CDK2/cyclin E initiates centrosome duplication remains elusive, although several downstream 
targets are implicated, including nucleophosmin (NPM) [40], Mps1 [41], and CP110 [42].  
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The centriole assembly process begins with the activation of polo-like kinase 4 (Plk4). 
Activated Plk4 localizes at the proximal end of the mother centriole, and recruits downstream 
structural proteins such as Sas-6, which triggers the assembly of the cartwheel structure and also 
the whole centriole by further recruiting other proteins like Sas-5 and Sas-4 [43-45]. Because of 
its central function in initiating new centriole formation, down-regulation of Plk4 inhibits 
centrosome duplication [46], and over-expression leads to centrosome over-duplication (>2 
centrosomes/cell) [43]. However, the exact mechanisms how cells regulate Plk4 activity during 
cell cycle are not fully understood. It seems that Plk4 regulates its own phosphorylation to 
maintain homeostatic Plk4 levels and centrosome numbers, and phosphorylated Plk4 is degraded 
through a SCF-Slimb/βTrCP-E3 ubiquitin ligase-dependent mechanism [47-50].  
Centrosomes mainly function as the primary microtubule organization center (MTOC) to 
nucleate microtubules which participate in numerous cellular functions such as defining cell 
polarity [51], cell migration [52], protein transportation [53], and most importantly mitosis [54]. 
Therefore centrosome abnormalities can lead to cellular defects in both interphase and mitosis. 
Recent results from our lab showed that excess centrosomes affect microtubule nucleation and 
dynamics, contributing to disrupted interphase behavior [18,55]. During mitosis, the two newly 
separated centrosomes localize at different poles of a cell to assist the formation of a mitotic 
spindle, which ensures the proper and accurate segregation of chromosomes. As a result, 
centrosome abnormalities, such as centrosome over-duplication which occurs frequently in most 
tumor cells [56], can compromise chromosome segregation. 
The idea that centrosome over-duplication is correlated with tumorigenesis dates back to 
more than 100 years ago, first proposed by the German biologist Theodor Boveri [21], and it was 
demonstrated that centrosome over-duplication is strongly associated with aneuploidy and 
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chromosome instability (CIN), which refers to the phenotype that cells constantly undergo 
chromosome missegregation and fail to maintain chromosome stability [57-59]. Originally it was 
believed that excess centrosomes (>2 centrosomes/cell) lead to the formation of multipolar 
spindles to induce CIN because excess centrosomes and multipolar spindles are frequently 
detected in tumors with CIN [60,61]. However, most daughter cells from multipolar division do 
not survive because they lack sufficient genetic information [62]. Therefore, the idea of 
multipolar spindle-induced CIN creates a paradox, which is resolved by recent literature 
demonstrating that centrosome over-duplicated cells still undergo classic bi-polar cell division by 
clustering centrosomes [62]. In this model, daughter cells develop low-level of aneuploidy and 
CIN from merotelic attachment without compromising their fitness. However, most of these 
findings were based on results in tumor cells, and the effects of excess centrosomes on primary 
cells remain elusive.  
 
C. p53 
I found that excess centrosomes activate p53 and phosphorylates p53 at ser33 in EC. 
This section summarizes the structure, regulations and functions of p53.  
p53 is a tumor suppressor protein which does not function correctly in most human 
cancers, and is mutated in about 50% of tumors [63]. It was first identified as a target protein of 
the T antigen of the virus SV40, which induces tumor development [64-67]. Originally, p53 was 
considered as an oncogene because it was over-expressed in some tumor cells [68,69]. However, 
later examinations of p53 in both tumors and normal cells revealed the tumor suppressing 
function of p53, and demonstrated that highly-expressed p53 in tumor cells are actually p53 
mutants [70,71].  
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Human p53 is a transcription factor with 393 amino acids, which can be divided to 5 
major domains: the N-terminal transactivation domain (NTD), the Pro-rich domain (PRD), the 
central DNA binding domain (DBD), the tetramerization domain (TD) and the C-terminal basic 
domain (BD) [72,73]. NTD interacts with many transcriptional factors such as TFIID and TFIIH 
to promote target gene expression [74,75]. DBD binds DNA, and confers specificity in selecting 
target genes. The consensus binding sequences of DBD are 5’-RRRC(A/T)(T/A)GYYY-(n)-
RRRC(A/T)(T/A)GYYY-3’, where n=0-13, and R and Y stand for purine and pyrimidine, 
respectively [76]. TD is required for p53 tetramerization [77,78], which is essential for DNA 
binding, protein interaction and post-translational modifications (PTM) [79].   
MDM2 is a well-known regulator of p53, although other regulators have been reported. 
MDM2 functions as the E3 ubiquitin-protein ligase, binds TAD of p53, and mark p53 for 
proteasomal degradation [80,81]. Increased levels of MDM2, frequently detected in some tumor 
types, result in enhanced degradation of p53, and contribute to tumor development [82,83]. 
Interestingly, MDM2 is also a downstream target of p53, creating a feedback loop to auto-
regulate its own levels [84]. This delicate system ensures that the steady-state levels of p53 are 
precisely controlled until it is activated by stress signaling.  
p53 can be activated by several cell stress signals such as DNA damage [85,86], 
deregulated oncogene expression [87] and hypoxia [88]. p53 activation requires its stabilization, 
which is dependent on the PTM on p53. Phosphorylation of p53 is usually considered as the first 
step of p53 stabilization by blocking the physical association between p53 and MDM2, and 
inhibiting the ubiquitination of p53 [89]. For example upon DNA damage, several kinases (e.g. 
ATM and ATR) will phosphorylate p53 at Ser15 and Ser20 to alleviate its inhibition by MDM2, 
and to stabilize and activate p53 [90-93]. Another amino acid, Ser46, can also be phosphorylated 
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upon stress stimulation, and this particular phosphorylation event seems critical for p53-induced 
apoptosis and replicative senescence [94,95]. Furthermore, osmotic shock induces p38-
dependent Ser33 phosphorylation [96], which is also involved in oncogene-induced senescence 
[97].  
Although some results suggest that p53 can function without its transcriptional activation 
activity [98,99], activated p53 mainly affects cell behavior by inducing the expression of various 
downstream target genes such as p21 [100], 14-3-3σ [101], Puma [102] and p53AIP1 [94]. These 
targets are differentially involved in various p53 activation-dependent effects. 
One important function of p53 is to induce cell cycle arrest, serving as an important cell 
cycle checkpoint mechanism. p53 can use multiple pathways to arrest stress-stimulated cells, and 
the signaling is extremely complex. Mainly p53 arrests cells at G1/S and G2/M transition. p21, 
the downstream target of p53, can bind and inhibit CDK2/cyclin E, which is required for G1/S 
progression [103], therefore arresting cells at G1 phase. p53 can also promotes G2/M arrest by 
inhibiting Cdc2 via p21, 14-3-3σ and several other targets [104].   
In addition to cell cycle arrest, stress-induced p53 promotes apoptosis, i.e. programmed 
cell death, by activating the expression of multiple pro-apoptotic proteins like Puma [102] and 
p53AIP1[94], which initiate the apoptotic pathway. Another important outcome of p53 activation 
is permanent cell cycle arrest, i.e. senescence [105] (see below). It seems that whether cells 
undergo cell-cycle arrest, apoptosis or senescence is dependent on cell type and stress, and the 
mechanisms for differential cell destiny are not fully understood [106].  
Recent evidence suggests that loss of centrosome integrity activates p53. Loss of 
centrosome integrity via down-regulation of important centrosome proteins induces p53-
dependent cell cycle arrest [107,108]. In addition, inhibition of centrosome assembly by 
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knocking out Sas-4 activates p53-dependent apoptosis in mouse embryos [109]. These findings 
suggest that p53 is critically involved in a “centrosome integrity checkpoint” to ensure a 
complete centrosome structure and function.  
Loss of p53 can induce centrosome over-duplication. In 1996, results from Vande Woude 
group demonstrated that centrosome over-duplication is frequently detected in mouse embryonic 
fibroblasts (MEF) from p53 knockout mice, indicating that p53 is involved in regulating 
centrosome duplication [110]. Two theories may explain the p53 loss-induced centrosome over-
duplication: p53 controls the initiation of centrosome duplication, and/or p53 serves as a 
surveillance mechanism for over-duplicated centrosomes. 
It is not surprising that p53 may be involved in the initiation of centrosome duplication 
because p53 upregulates p21, which inhibits CDK2/cyclin E, the initiator of centrosome 
duplication. In support with this pathway, p21 deficiency induces centrosome over-duplication 
by triggering a bona fide centriole over-duplication phenotype [111,112]. In addition, re-
introduction of p21 in p53
-/-
 cells partially rescued their centrosome duplication cycles [113].  
However, there are contradictory results about whether cells have a p53-dependent 
surveillance mechanism for centrosome over-duplication. In 2001, Andreassen et al. 
demonstrated that cells possess a p53-dependent tetraploid checkpoint which responds to 
centrosome over-duplication and tetraploid genome resulting from failed cytokinesis [114]. 
However, this notion was later questioned by other findings showing “tetraploid checkpoint” 
may be an artifact of drug overdose and a side effect of DNA damage [115,116]. In line with the 
idea that no checkpoint detects centrosome over-duplication, cells with excess centrosomes tend 
to routinely undergo bipolar cell division and produce viable daughter cells  [62]. However, 
several recent results suggest that cells may actually have a p53-depdendent mechanism for 
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monitoring extra centrosomes. Induction of extra centrosomes by over-expressing a CDK6 
activator induces p53-dependent apoptosis [117]. In addition, extra centrosomes induced by Plk4 
over-expression seem to stabilize and activate p53 [49,118]. However, the mechanisms and 
effects of excess centrosomes-induced p53 stabilization remain elusive.  
 
D. Senescence 
I found that excess centrosomes induce p53-dependent senescence in primary EC, 
establishing the first link between excess centrosome and senescence. This section summarizes 
current understandings of senescence. 
Cellular senescence denotes permanent cell cycle arrest. Unlike quiescent cells, senescent 
cells cannot go back to the cell cycle regardless of nutrient level or differentiation status. 
Senescence was first noticed and identified by Hayflick who found that cells have a doubling 
potential of ~50 passages in culture, referred as the Hayflick limit [119,120]. It was later found 
that the Hayflick limit is caused by shortened telomeres because DNA polymerases cannot fully 
replicate the lagging strands [121,122]. Shortened telomeres trigger a DNA damage response 
(DDR), which finally induces p53-dependent senescence [123,124].  
Besides telomere shortening, ectopic expression of oncogenes can also induce senescence. 
In 1997, Serrano et al. demonstrated that enforced expression of oncogenic Ras in primary 
human or rodent cells induces premature senescence [87], which is contradictory to the general 
perception of oncogene functions. Later studies showed that over-expression of BRAF or loss of 
tumor suppressors such as PTEN can also induce senescence [125,126], indicating that 
oncogene-induced senescence (OIS) is a general mechanism in cells to prevent cell 
transformation. It has been shown that the p38 MAPK contributes to oncogene-induced 
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senescence partially by phosphorylating p53 at Ser33 [97]. In addition to telomere shortening 
and oncogene over-expression, several genotoxic chemicals induce senescence, such as H2O2 
[127], etoposide [128], and hydroxyurea [129].  
Although there are no definite markers for cellular senescence, it is now well-accepted 
that senescence is a complicated and complex cellular program which alters cellular morphology, 
signaling and behaviors in multiple ways. First, most senescent cells, such as those induced by 
oncogene expression and H2O2, tend to have large and flat morphology [87,127]. Another 
prominent feature of senescence is the expression of senescence-associated β-galactosidase (SA-
β-gal), which can be detected by chemical reaction at pH 6 [130]. SA-β-gal activity is expressed 
from a lysosomal protein GLB1, which has optimal activity at pH 4.5 but markedly lower 
activity at pH 6 [131]. Because senescent cells accumulates high amount of GLB1, the 
cumulative activity of GLB1 becomes readily detectable at pH 6, representing the SA-β-gal 
activity [132]. However, no evidence suggests that SA-β-gal/increased GLB1 contributes to 
senescence progression [131]. Some senescent cells demonstrate senescence associated 
heterochromatic foci (SAHF) in their nuclei. In 2003, Narita et al. first described this phenotype, 
and demonstrated that histone H3 with methylated Lys 9 are concentrated in these SAHF [133], 
which is supported by following reports [134-136]. However, similar to SA-β-gal, SAHF is 
dispensable for senescence, and its occurrence depends on specific cell type and stress signals 
[137].  
Both SA-β-gal and SAHF seem to accompany the outcome of senescence without 
contributing to its development, but two other senescence markers, p53 and p16, are critically 
involved in senescence progression. As mentioned above, p53 is involved in senescence by 
mediating DNA damage response [123,124]. Additionally, p53 participates in oncogene-induced 
11 
senescence using similar mechanisms through DNA damage response [138]. p21, a downstream 
target of p53, is also involved in senescence. Ectopic expression of p21 induced premature 
senescence [139], and lack of p21 bypassed senescence in human fibroblasts [140]. Besides 
p53/p21, another CDK inhibitor, p16, is also critical for senescence.  p16 blocks the cell cycle at 
G1/S transition by binding and inhibiting CDK4/cyclin D and CDK6/cyclin D [141]. It is up-
regulated in several senescence scenarios, including those induced by telomere shortening 
[142,143] and oncogene over-expression [87].  In addition, ectopic expression of p16 induces 
premature senescence [139], and loss/inactivation of p16 extend the lifespan of human mammary 
epithelial cells [144,145]. Although it is not entirely clear how p16 and p53 interact with each 
other to participate in senescence program, the general concept is that DNA damage response or 
other stresses first activate p53 to induce transient cell cycle arrest, which progresses to stable 
and permanent arrest by inducing and maintaining p16 expression [146].  
It is not completely known why cells undergo senescence instead of apoptosis. One 
possible explanation may be related to the senescence-associated secretory phenotype (SASP) in 
senescent cells. It was shown that senescent cells demonstrate a strong inflammatory phenotype 
especially in fibroblasts [147], and many inflammatory-related factors are secreted by senescent 
cells, such as IL-1α/β [148,149], IL-6 [150], and IL-8 [151]. Therefore senescent cells can 
contribute to inflammatory response via SASP, therefore promoting cell proliferation, migration, 
and differentiation [152].  
Centrosome abnormalities (excess centrosomes and loss of centrosomes) are associated 
with, and sometimes contributes to, cell cycle arrest or senescence. Some replicatively and 
prematurely senescent MEF have excess centrosomes because of unidentified mechanisms [153]. 
In addition, down-regulation of centrosomal structural proteins, such as PCM-1 and γ-tubulin, 
12 
induces p53-dependent cell cycle arrest and senescence [107]. Inhibition of two other proteins, 
Aurora A and TACC3, which promote centrosome maturation, leads to premature senescence in 
tumor cells [154,155]. Therefore, centrosome abnormalities are associated with cellular 
senescence, but whether centrosome over-duplication leads to senescence remain to be 
elucidated.  
 
E. Summary 
Centrosome over-duplication is ubiquitously associated with bona fide tumor cells, and 
has been recently documented in tumor EC as well. The outcomes of centrosome over-
duplication in tumor EC are not completely understood, but may contribute to the abnormalities 
of tumor vasculature and the potential drug resistance in tumor angiogenic therapy. Recent 
evidence suggests that centrosome over-duplication activates a p53 stress pathway, although the 
exact mechanisms remain elusive. Better understanding of these pathways will contribute to 
further studies of centrosome function and its implications for disease.  
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F. Figure 
Figure 1.1. Structure of a centrosome 
A centrosome is comprised of two centrioles and the surrounding pericentriolar material (PCM, 
yellow). A centriole is a cylinder structure formed by 9 radially symmetric triplet microtubules. 
At the proximal end of a centriole, there is a cartwheel structure (red) with 9 triplet microtubules 
(green). At the distal end of a centriole, there are 9 doublet microtubules, which are modified and 
associated with subdistal and distal appendages (blue). 
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CHAPTER II-Tumor-Derived Factors and Reduced p53 Promote Endothelial Cell 
Centrosome Over-duplication
1
 
A. Summary 
Approximately 30% of tumor endothelial cells have over-duplicated (>2) centrosomes, 
which may contribute to abnormal vessel function and drug resistance. Elevated levels of 
vascular endothelial growth factor A induce excess centrosomes in endothelial cells, but how 
other features of the tumor environment affect centrosome over-duplication is not known. To test 
this, we treated endothelial cells with tumor-derived factors, hypoxia, or reduced p53, and 
assessed centrosome numbers. We found that hypoxia and elevated levels of bone 
morphogenetic protein 2, 6 and 7 induced excess centrosomes in endothelial cells through 
BMPR1A and likely via SMAD signaling. In contrast, inflammatory mediators IL-8 and 
lipopolysaccharide did not induce excess centrosomes. Finally, down-regulation in endothelial 
cells of p53, a critical regulator of DNA damage and proliferation, caused centrosome over-
duplication. Our findings suggest that some tumor-derived factors and genetic changes in 
endothelial cells contribute to excess centrosomes in tumor endothelial cells.  
                                                          
1
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B. Introduction 
Tumor progression requires angiogenesis, a hallmark of cancer development, and tumor 
vessels enable tumor metastasis by providing a conduit for tumor cell invasion and spread [1,2]. 
Although tumor vessels are a critical part of the tumor micro-environment, anti-angiogenic 
therapies have had no effect or provided transitory improvement, indicating that tumor vessels 
become resistant to angiogenesis inhibitors [3]. Consistent with the lack of effectiveness of anti-
angiogenic therapy, recent studies show that endothelial cells (EC) that line tumor vessels have 
genetic abnormalities such as aneuploidy. Aneuploidy is often associated with excess 
centrosomes, and up to 30% of tumor EC have excess centrosomes [4-6]. Centrosomes form the 
microtubule-organizing center (MTOC) in interphase cells to regulate cell migration, polarity, 
and adhesion, and they form the spindle poles that segregate chromosomes during mitosis [7]. 
Thus tumor EC acquire permanent structural and genetic alterations via excess centrosomes that 
likely contribute to the phenotypic and functional abnormalities of tumor blood vessels.  
Tumor blood vessels are thought to arise from normal vessels that enter the tumor [8,9], 
suggesting that the environment is responsible for inducing excess centrosomes in EC. Tumor 
cells secrete elevated levels of various growth factors [10], and our previous work showed that 
elevated levels of vascular endothelial growth factor A (VEGF-A) induce centrosome over-
duplication in EC [11]. However, the frequency of centrosome over-duplication in tumor-derived 
EC is significantly higher than that induced by excess VEGF-A [6,11]. Thus other up-regulated 
signaling pathways in the tumor environment likely contribute to centrosome over-duplication in 
EC. For example, bone morphogenetic protein (BMP), which is required for appropriate 
angiogenesis, is up-regulated in certain cancers [12]. Furthermore, different BMP ligands such as 
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BMP2, BMP4, BMP6 and BMP7 induce angiogenesis [13], and BMP2 and BMP4 promote 
tumor angiogenesis [13]. 
In addition to growth factors, the tumor environment is hypoxic and has elevated levels 
of inflammatory cytokines. The tumor environment is hypoxic in part because of abnormal tumor 
blood vessels [14]. Hypoxia activates the hypoxia-inducible factor (HIF) family of transcription 
factors, which further induce expression of numerous downstream targets, including VEGF-A 
[15]. Inflammation is also a hallmark of the tumor environment and is thought to promote tumor 
growth [16], perhaps via secretion of angiogenic chemokines such as Interleukin 8 (IL-8) that 
induce tumor angiogenesis [17]. It is not known whether hypoxia or inflammation promote 
excess centrosomes in EC.  
In this report, we analyzed the effects of specific inputs elevated in the tumor 
environment on centrosome over-duplication in EC. We found that elevated levels of some BMP 
ligands are sufficient to induce centrosome over-duplication in EC, using BMP receptor 1A and 
likely via downstream SMAD signaling. Additionally, hypoxia promoted EC centrosome over-
duplication through a VEGF-A-independent mechanism. In contrast, inflammatory mediators did 
not affect centrosome numbers in EC. In addition to environmental factors, down-regulation of 
the tumor-suppressor p53 induced centrosome over-duplication in EC. These results indicate that 
both environmental and genetic factors contribute to centrosome over-duplication in EC, and 
may contribute to the high frequencies seen in tumor vessels. 
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C. Materials and Methods 
Cell culture 
Human umbilical vein endothelial cells (HUVEC, Lonza Group cc-2519), human brain 
microvascular endothelial cells (HBMEC, Cell Systems ACBRI 376) and human umbilical artery 
endothelial cells (HUAEC) were cultured in endothelial growth medium-2 (EGM-2, Lonza 
Group cc-3162). Human lung microvascular endothelial cells (HMVEC-L, Lonza Group cc-2527) 
were cultured in EGM-2 MV (Lonza Group cc-3102). Normal mouse EC (NEC) were originally 
isolated from mouse mammary glands and cultured in EGM-2 [6]. Growth factors or 
lipopolysaccharide (LPS, List Biological Laboratories 201) were added to cultures at indicated 
concentrations. Exogenous recombinant growth factors used in this study were VEGFA-165 
(PeproTech 100-20), BMP2 (R&D Systems 355-BM-010), BMP4 (R&D Systems 314-BP-010), 
BMP6 (R&D Systems 507-BP-020), BMP7 (R&D Systems 354-BP-010), and Interleukin-8 (IL-
8, PeproTech 200-08). VEGF-A and BMP were used at 200 ng/ml, and IL-8 was added at 
indicated concentrations. Culture medium was replaced daily for 4 days, and cells were 
maintained at 30-70% confluence. To study signaling, HUVEC were cultured in Opti-MEM for 
4 hr before treatment with 200 ng/ml BMP ligands in Opti-MEM for 30 min.  
Lipofectamine RNAiMAX (Life Technologies 13778-150) was used for siRNA 
transfection according to manufacturer protocols. siRNAs were: non-targeting siRNA (Life 
technologies 4390847), BMPR1A siRNA (Life technologies 4392420-s280), BMPR1B siRNA 
(Life technologies 4392420-s2043) and BMPR2 siRNA (Life technologies 4390824-s2046). 
For hypoxia experiments, HUVEC were cultured in 2% or 3% O2 for 4 days. 1 μg/ml of 
recombinant human VEGF Receptor-1 (Flt-1)/Fc (R&D Systems 321-FL-050) was added to 
medium to block VEGF-A signaling [18], and the medium was changed daily. In general, EC 
33 
were immediately fixed with cold MeOH after hypoxic incubation. To test for translocation of 
HIF1α, EC were recovered in normoxia for 30 min before fixation. Hypoxic-mimetic agent 
desferrioxamine (DFO) and a hypoxia incubator chamber were kindly provided by Dr. Kimryn 
Rathmell.  
 
Immunofluorescence and microscopy 
HUVEC were fixed in ice cold 100% MeOH for 10 min, then stained as previously 
described [19]. Briefly, fixed cells were blocked in 5% bovine serum in PBS for 1hr at room 
temperature (RT), then incubated with mouse anti-human γ-tubulin (1:5000, Sigma-Aldrich 
T6557), rabbit anti-human pSmad1/5 (1:500, Cell Signaling 9516) or mouse anti-human HIF1α 
(1:50, Novus biologicals NB100-105) at 4
0
C overnight. After washing 3X 5 min in PBS, cells 
were incubated with secondary antibodies (1:250), including goat-anti-mouse Alexa 488 
(Invitrogen A11029) or goat-anti-mouse Alexa 594 (Invitrogen A11005), and DRAQ7 (1:1000, 
Abcam ab109202) or SYTOX green (1:50,000, Invitrogen S7020), for 2hr at RT. Both primary 
and secondary antibodies were diluted in 5% bovine serum in PBS. Centrosome numbers were 
determined using a Zeiss LSM 5 Pascal microscope with a 100X objective.  
pSMAD1/5 fluorescence intensities were quantified in ImageJ. Briefly, the DRAQ7 
(nucleus) channel from compressed z-stacks was thresholded to segment nuclei and adjusted into 
a binary image. Intensity analysis was redirected from the binary image to the pSMAD1/5 
channel by changing the “Set Measurements” parameter. “Analyze Particles” function was 
executed to determine pSMAD1/5 intensity in each nucleus.  
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Western blot 
Western blot analysis was performed as previously described, with slight modifications 
[11]. Briefly, HUVEC lysates were lysed using RIPA buffer supplemented with protease 
inhibitor (Cell Signaling 5871S). Proteins were separated on a 10% sodium dodecyl sulfate–
polyacrylamide gel, transferred to a PVDF membrane (GE Healthcare, RPN303F), and blocked 
in 5% bovine serum albumin (BSA) in PBS with 1% tween-20 (Sigma P2287) for 1h at RT. 
Primary antibodies used were: rabbit anti-phospho-Smad1/5 (1:1000, Cell Signaling 9516), 
rabbit anti-Akt (1:1000, Cell Signaling 9272), rabbit anti-phospho-Akt (Ser473) (1:1000, Cell 
Signaling 4060), rabbit anti-phospho-ERK1/2 (Thr202/Tyr204) (1:1000, Cell Signaling 4370), 
rabbit anti-ERK 1/2 (1:1000, Cell Signaling 4695), mouse anti-HIF1α (1:500, Novus biologicals 
NB100-105), mouse anti-p53 (1:1000, Abcam ab1101) and rabbit anti-p53 (1:500, Abcam 
ab131442). Membranes were incubated with primary antibodies diluted in 1% BSA overnight at 
4
0
C. Signal was detected with horseradish peroxidase (HRP) anti-rabbit (1:5000, Invitrogen G-
21234) or HRP anti-mouse (1:30,000, Invitrogen 81-6720), and imaged via Clarity Western ECL 
Substrate (Bio-Rad 170-5061).  
 
Quantitative real-time PCR 
HUVEC were collected 48 hr after siRNA transfection, and total RNA was isolated with 
TRIZOL (Life technologies 15596-026) according to the manufacturer’s protocol. 1 µg of RNA 
was used for synthesizing cDNA with iScript (Bio-Rad 1708891). cDNA products were diluted 
fivefold. For measuring BMPR1B, BMPR2 and GAPDH, 0.5 ul of diluted samples were used as 
templates; for BMPR1A, 5 ul of diluted samples were used. RT-PCR was preformed using iTaq 
universal SYBR Green supermix (Bio-Rad 1725121) in a 7900HT fast RT-PCR system (Applied 
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Biosystems). Primer sequences were: GAPDH (forward: 
CCTCAAGATCATCAGCAATGCCTCCT; reverse: 
GGTCATGAGTCCTTCCACGATACCAA), BMPR1A (forward: 
AGCTACGCCGGACAATAGAA; reverse: CTATGACAACAGGGGGCAGT), BMPR1B 
(forward: GCCTGCCATAAGTGAGAAGC; reverse: CTTTCTTGGTGCCCACATTT), and 
BMPR2 (forward: GGTAAGCTCTTGCCGTCTTG; reverse: ATCTCGATGGGAAATTGCAG). 
 
Lentivirus infection 
Human p53–targeted shRNA (clone ID: V3LHS_333920) with pGIPZ vector was 
obtained from Open Biosystems. Mouse p53–targeted shRNA clone (TRCN0000012360) with 
pLKO.1 vectors were obtained from the UNC Lenti-shRNA Core facility. shRNA lentiviruses 
were made by the UNC Lenti-shRNA Core facility. Cells were infected with 100 μl/ml lentivirus 
in 5 ml medium plus 1μg/ml polybrene (Millipore) overnight at 37°C, then incubated for 4 days 
before fixation or collection. Virus lacking a target sequence (empty vector) was used as a 
control. 
 
Statistical analysis 
The paired or unpaired two-tailed Student’s t-test was used to determine statistical 
significance in cases with 3 repeats. The 2 test was used to determine statistical significance in 
cases with 2 repeats. Error bars represent standard deviation from mean between experiments. 
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D. Results 
Elevated levels of BMP ligands induce excess centrosomes in EC 
We began to dissect the different potential inputs to excess centrosome formation from 
the tumor environment by introducing elevated levels of different signaling pathways or by 
genetic manipulation of normal EC and assessing effects on centrosome over-duplication. 
Because BMP ligands regulate angiogenesis and are expressed in the tumor micro-environment, 
we asked whether elevated BMP signaling regulates centrosome number in EC. HUVEC treated 
with different BMP ligands were stained with anti-γ-tubulin antibodies to label centrosomes, and 
EC with different centrosome numbers were clearly identified (Supp. Fig 2.1A). As previously 
described, EC with 3 or more centrosomes were considered to have excess centrosomes (Fig 
2.1A) [19]. Exposure to BMP2, BMP6, or BMP7 caused a significant increase in the percentage 
of HUVEC with excess centrosomes (Fig 2.1B-C, Fig 2.2A). This effect was not observed with 
BMP4 treatment in HUVEC (Supp. Fig 2.1B), nor upon treatment with BMP2 or BMP6 in 
HUAEC, HBMEC or HMVEC-L (Supp. Fig 2.1C-E). These results indicate that some but not 
all BMP ligands induce excess centrosomes, and that different EC isolates respond differently to 
these ligands.  
 
BMP-induced centrosome over-duplication is BMP receptor type 1A (BMPR1A)-dependent 
To understand the mechanism of BMP-induced centrosome over-duplication, we down-
regulated BMP receptors in HUVEC. There are several BMP-specific receptors that include type 
1A BMP receptor (BMPR1A/ALK3), type 1B BMP receptor (BMPR1B/ALK6), and type 2 
BMP receptor (BMPR2) [20]. siRNA targeting of these three receptors efficiently and 
significantly knock-down their mRNA levels (Supp. Fig 2.2A-C). The increase in EC with 
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excess centrosomes seen with BMP2 or BMP6 was blocked by BMPR1A knockdown, but not by 
BMPR1B or BMPR2 knockdown (Fig 2.2A-B). These findings suggest that BMPR1A is 
required for BMP-induced centrosome over-duplication.  
Type 1 and type 2 BMP receptors form hetero-tetramers upon ligand binding that permits 
phosphorylation of downstream effectors called receptor-regulated SMAD (R-SMAD), including 
SMAD1 and SMAD5. Phosphorylated R-SMADs bind SMAD4 to translocate into the nucleus 
and modulate gene expression [20]. To further understand the mechanism of BMP-induced 
centrosome over-duplication, we examined the phosphorylation of SMAD1/5 by 
immunofluorescence. The levels of nuclear phospho-SMAD1/5 (pSMAD1/5) were significantly 
induced by BMP6 treatment in control siRNA, BMPR1B siRNA and BMPR2 siRNA-treated 
HUVEC, but not in BMPR1A siRNA-treated cells (Fig 2.2C-D), which was also confirmed by 
western blot (Fig 2.2E). These results suggest that BMPR1A is required for BMP-induced 
centrosome over-duplication through downstream R-SMAD activation.  
 
Inflammatory mediators do not promote excess centrosomes in EC 
Chronic inflammation-associated signaling, which is activated by up-regulation of 
cytokines, is another characteristic of the tumor environment. IL-8 is a pro-inflammatory 
cytokine that regulates angiogenesis [21]. To determine if IL-8 promotes centrosome over-
duplication in EC, we treated HUVEC with IL-8, which induced ERK phosphorylation in 
HMVEC (Supp. Fig 2.3); however, these levels of IL-8 did not induce excess centrosomes (Fig 
2.3A). To test more general effects of inflammation on centrosome over-duplication, HUVEC 
were treated with lipopolysaccharide (LPS), a potent pro-inflammatory agent that promotes 
secretion of a wide range of inflammatory mediators [22]. Consistent with the results of IL-8 
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treatment, LPS treatment did not induce significant increases in excess centrosomes in HUVEC 
(Fig 2.3B). These results indicate that IL-8 and LPS do not induce centrosome over-duplication 
in EC, suggesting that inflammatory mediators are not causative agents in generating excess 
centrosomes in EC.   
 
Hypoxia induces excess centrosomes in EC 
In addition to the complex milieu of cytokines and growth factors, tumor environments 
are often hypoxic. To determine whether hypoxia induces excess centrosomes in EC, HUVEC 
were first treated with the oxygen chelating agent desferrioxamine (DFO), which mimics 
hypoxia in inducing HIF1α accumulation [23]. Treatment with DFO resulted in a 4-fold increase 
in the frequency of excess centrosomes compared to controls (Fig 2.4A). To further test our 
hypothesis, HUVEC were cultured in a 2-3% oxygen environment (hypoxia) for 4 days, then 
fixed and stained to assess the frequency of centrosome over-duplication. Hypoxic incubation led 
to translocation of HIF1α from the cytoplasm to the nuclear compartment of EC (S4A Fig 2.), 
and also induced accumulation of HIF1α (Supp. Fig 2.4B), indicating the activation of hypoxia 
pathways. Incubation in 2% or 3% oxygen significantly promoted centrosome over-duplication 
compared to normoxic controls (Fig 2.4B, Supp. Fig 2.4C). These results indicate that a hypoxic 
environment is sufficient to induce excess centrosomes in EC.  
Hypoxia up-regulates the production and release of pro-angiogenic cytokines such as 
VEGF-A in multiple tissues [15]. To determine whether hypoxia-induced centrosome over-
duplication in EC requires VEGF-A signaling, HUVEC were incubated in hypoxic conditions 
with recombinant human soluble VEGF Receptor-1 (Flt-1)/Fc to block VEGF-A signaling. Flt-
1/Fc treatment efficiently inhibited ERK phosphorylation induced by VEGF-A (Supp. Fig 2.4C), 
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but was unable to rescue hypoxia-induced centrosome over-duplication (Fig 2.4C). This result 
suggests that hypoxia induces excess centrosomes in EC through VEGF-A-independent 
mechanisms. 
 
Inhibition of p53 signaling induces excess centrosomes in EC 
Loss or inactivation of p53 induces excess centrosomes in mouse embryonic fibroblasts 
[24]. Thus, we tested whether p53 attenuation leads to excess centrosomes in EC. A short-hairpin 
RNA (shRNA) was used to down-regulate p53 levels in HUVEC (Supp. Fig 2.5A), and HUVEC 
infected with shRNA had an approximately 3-fold increase in the percentage of excess 
centrosomes (Fig 2.5A). Previous studies demonstrated that mouse tumor stromal cells, 
including mouse tumor EC, have an attenuated p53 response [25]. Therefore we asked whether 
down-regulation of p53 induced excess centrosomes in mouse EC by infecting immortalized 
normal mouse EC (NEC) [6] with p53 shRNA. Down-regulation of mouse p53 also induced 
excess centrosomes in NEC (Supp. Fig2.5B, Fig 2.5B). These results suggest that down-
regulation of p53 contributes to centrosome over-duplication in tumor EC.  
 
E. Discussion 
We previously showed that high levels of the pro-angiogenic growth factors VEGF-A 
and bFGF promote excess centrosomes in EC [11].  However, the frequency of EC centrosome 
over-duplication, even with a combination of both VEGF-A and bFGF, was much less than that 
seen in primary isolates of tumor-derived EC [6], suggesting that other aspects of the tumor 
environment contribute to pathological centrosome over-duplication. Here we provide evidence 
that excess centrosomes in EC occur downstream of numerous tumor-related inputs. We found 
40 
that the BMP ligands BMP2, BMP6 and BMP7 significantly induced centrosome over-
duplication, while inflammatory mediators were ineffective. Hypoxia, which is associated with 
most solid tumors, induced excess centrosomes in EC through VEGF-A-independent 
mechanisms. Besides environmental factors, cell-autonomous perturbation of p53 also promoted 
excess centrosomes in EC. These findings suggest that multiple inputs contribute to the high 
frequency of tumor vessel-derived EC with excess centrosomes.  
Elevated levels of some BMP ligands, similar to high levels of VEGF and FGF ligands, 
induce excess centrosomes in EC. Interestingly, VEGF and FGF signaling are mediated by 
VEGF receptor 2 and FGF receptor, respectively, which belong to the tyrosine kinase receptor 
family [26], whereas BMP signals through serine/threonine kinase receptors [27], suggesting that 
diverse signaling inputs promote centrosome over-duplication in EC. Our results also show 
ligand and cell type specificity of BMP in inducing excess centrosomes: BMP2, BMP6 and 
BMP7, but not BMP4, significantly induced excess centrosomes in HUVEC, whereas BMP2 and 
BMP6 did not significantly affect centrosome numbers in several other human primary EC.  
BMP ligands initiate signal transduction by binding a hetero-tetrameric receptor 
comprised of two dimers of type 1 and type 2 receptors [20].  Among a group with specificity for 
TGFβ and/or BMP signaling, BMPR1A, BMPR1B and BMPR2 are specific to BMP ligands [20]. 
Here we show that knockdown of BMPR1A, but not BMPR1B or BMPR2, inhibits BMP-
induced SMAD1/5 phosphorylation and centrosome over-duplication. BMPR1A is critically 
involved in BMP signaling, and BMPR1A knockout mice are embryonically lethal with severe 
heart valve and EC defects [28-30]. However, BMPR1B knockout are viable [31]. In line with 
the in vivo data, previous in vitro data showed that BMPR1A siRNA, but not BMPR1B siRNA, 
abrogates SMAD1/5 phosphorylation in human microvascular endothelial cells [32]. These 
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results are consistent with our findings. Interestingly, BMPR2 knockdown did not inhibit SMAD 
activation or block BMP ligand-induced centrosome over-duplication, indicating possible 
redundancy of type 2 receptors in EC. This is also consistent with previous finding that ablation 
of BMPR2 in pulmonary artery smooth muscle cells allows signaling through ActR2A and does 
not abolish BMP signaling [33].  
Another prominent feature of the tumor environment is a chronic inflammatory response, 
which is mediated by infiltration of immune system cells [34]. Tumor inflammation is similar to 
inflammation associated with normal physiological processes such as wound healing [34]. Our 
results suggest that inflammatory mediators do not induce centrosome over-duplication in EC. 
Thus, despite being a hallmark of the tumor environment, chronic inflammation is likely not an 
input for centrosome over-duplication in tumor EC. This finding also suggests that during 
physiological inflammation, EC do not develop excess centrosomes, therefore maintaining a 
relatively normal phenotype and function.  
Hypoxia upregulates the expression and secretion of growth factors, such as VEGF-A, in 
the tumor environment [35]. Here we show that hypoxia induces excess centrosomes in EC. 
However, although hypoxia-induced signaling up-regulates VEGF-A, which promotes 
centrosome over-duplication [11], our data suggest that hypoxia-induced excess centrosomes in 
EC are independent of EC-derived VEGF-A. This indicates that, if tumor EC undergo 
centrosome over-duplication as a result of up-regulated VEGF-A signaling in the tumor 
environment, the source of the ligand is likely the tumor cells or other non-endothelial stromal 
cells. 
In addition to changes in the tumor environment, tumor EC may also acquire cell-
autonomous perturbations that promote centrosome over-duplication. Previous studies showed 
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that tumor stromal cells, including tumor EC, have attenuated p53 activation in response to stress 
stimulation [25], and p53 abnormalities have been linked with centrosome over-duplication. For 
example, mouse embryonic fibroblasts isolated from p53 knock-out mice possess multiple copies 
of functional centrosomes [24]. Here we show that reduced p53 levels induced excess 
centrosomes in EC, suggesting that cell autonomous p53 changes contribute to centrosome over-
duplication in tumor EC. 
Although up to 30% of primary tumor EC have excess centrosomes [6], our results 
indicate that no single environmental factor or down-regulation of p53 alone achieves such a 
high percentage of excess centrosomes in EC [11]. It is possible that in vivo, several inducing 
factors combine to achieve the high percentage of excess centrosomes in tumor EC. In summary, 
we show that multiple environmental inputs and attenuated p53 contribute to centrosome over-
duplication in EC. This work contributes to our understanding of both normal and tumor 
angiogenesis, and provides potential insights for anti-angiogenic therapy.  
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F. Figures 
Figure 2.1. BMP2 and BMP7 induce excess centrosomes in EC.  
(A) Representative images of HUVEC with normal (left) and over-duplicated centrosomes 
(right). HUVEC were stained with γ-tubulin for centrosomes (green) and DRAQ7 for nuclei 
(blue). (B, C) Frequency of excess centrosomes in HUVEC after treatment with 200 ng/ml 
BMP2 (B) or BMP7 (C) for 4 days. Error bars, standard deviation from mean. Statistics: two-
tailed unpaired Student’s t-test. *, p≤0.05. 
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Figure 2.2. BMP-induced centrosome over-duplication is dependent on BMPR1A. 
(A, B) Frequency of excess centrosomes in indicated siRNA-treated HUVEC cultured with 
vehicle or 200 ng/ml of BMP6 (A) or BMP2 (B) for 4 days. C, non-targeting control siRNA; 
R1A, BMPR1A siRNA; R1B, BMPR1B siRNA; R2, BMPR2 siRNA. (C) Representative images 
of HUVEC treated with indicated siRNA and vehicle or BMP6 and stained for phospho-
SMAD1/5 (pSMAD1/5, green) and nucleus (DRAQ7, blue). Cells were starved in Opti-MEM 
for 4 hr, followed by 30 min treatment with vehicle or BMP6. Only the nuclear pSMAD1/5 is 
shown (see Methods for details of mask). (D) Quantification of nuclear pSMAD1/5 in HUVEC 
treated as indicated. (E) Western blot of phospho-SMAD1/5 (pSMAD) and total SMAD1 in 
HUVEC treated as indicated. Cells were starved in Opti-MEM for 4 hr, then treated with vehicle 
or BMP6 for 30 min. Error bars, standard deviation from mean. Statistics: two-tailed paired (A, 
B) or unpaired (D) Student’s t-test. ns, not significant; *, p≤0.05; **, p≤0.01; ***, p≤0.001. 
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Figure 2.3. Inflammatory mediators do not induce excess centrosomes in EC.  
(A) Frequency of excess centrosomes in HUVEC after treatment with indicated factors for 4 
days. (B) HUVEC incubated with 10 ng/ml LPS for 4 days prior to determination of excess 
centrosome frequency. Results are shown in fold of increase, and each frequency was normalized 
to its respective control. Error bars, standard deviation from mean. Statistics: Two-tailed 
unpaired Student’s t-test (A), Χ2 test (B). *, p≤0.05; ns, not significant. 
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Figure 2.4. Hypoxia induces excess centrosomes in EC independent of cell-autonomous 
VEGF-A signaling.  
(A) Frequency of excess centrosomes in HUVEC after treatment with 100 μM hypoxic-mimetic 
agent desferrioxamine (DFO) for 4 days. (B) Frequency of excess centrosomes in HUVEC after 
4 days of incubation in 2% oxygen. (C) Frequency of excess centrosomes in HUVEC after 
incubation in 20% or 2% oxygen for 4 days and indicated treatments. Error bars, standard 
deviation from mean. Statistics: two-tailed unpaired Student’s t-test. *, p≤0.05; ns, not 
significant.  
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Figure 2.5. Down-regulation of p53 induces excess centrosomes in EC.  
(A) Frequency of excess centrosomes in HUVEC infected with human p53 shRNA. (B) 
Frequency of excess centrosomes in normal mouse endothelial cells (NEC) infected with mouse 
p53 shRNA. Error bars, standard deviation from mean. Statistics: two-tailed unpaired Student’s 
t-test. *, p≤0.05. 
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Supplementary Figure 2.1. Effects of BMP ligands on human primary EC. 
(A) Representative images of HUVEC with different centrosome numbers (n). (B) Frequency of 
excess centrosomes in HUVEC after treatment with 200 ng/ml of BMP4 for 4 days. (C-E) 
Frequency of excess centrosomes in HUAEC (C), HBMEC(D), or HMVEC-L (E) after treatment 
with 200 ng/ml of BMP2 or BMP6 for 4 days. Error bars, standard deviation from mean. 
Statistics: two-tailed unpaired Student’s t-test. ns, not significant. 
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Supplementary Figure 2.2. Validation of BMP receptor siRNAs.  
(A-C) Relative mRNA levels of BMPR1A (A), BMPR1B (B), or BMPR2 (C) in HUVEC treated 
with indicated siRNAs. Cells were collected 48 hr after siRNA treatment. Error bars: standard 
deviations from mean. Statistics: two-tailed unpaired. *, p≤0.05; ***, p≤0.001. 
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Supplementary Figure 2.3. Elevated IL-8 activates ERK phosphorylation.  
HMVEC were treated with 200 ng/ml IL-8 or VEGF-A for indicated times, collected, and 
analyzed for phosphorylated ERK (pERK) and total ERK. 
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Supplementary Figure 2.4. Hypoxia activates HIF1α and Flt-Fc blocks VEGF-A signaling.  
(A) HUVEC were MeOH fixed immediately (lower panel) or after 30-min recovery in normoxia 
(top panel) post-hypoxic incubation, then stained for HIF1α (red) and DRAQ7 (DNA, green). (B) 
Western blot for HIF1α in HUVEC incubated in normoxia or 2% oxygen. (C) Frequency of 
excess centrosomes in HUVEC after incubation in 3% O2 for 4 days. (D) HUVEC were treated 
with VEGF-A (200 ng/ml) or VEGF-A plus Flt-Fc (1 ug/ml) for 20 min. Cell lysates were 
collected and blotted for phosphorylated ERK (pERK) and total ERK. Error bars, standard 
deviation from mean. Statistics: two-tailed unpaired Student’s t-test. *, p≤0.05. 
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Supplementary Figure 2.5. Validation of p53 shRNA.  
HUVEC (A) or mouse normal endothelial cells (NEC) (B) were infected with viruses expressing 
human p53 shRNA or mouse p53 shRNA, respectively. p53 levels were detected by western blot 
4 days after viral infection. 
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CHAPTER III-Excess Centrosomes Induce p53-Dependent Senescence without DNA 
Damage in Endothelial Cells
2
 
A. Summary 
Tumor blood vessels support tumor growth and progression. Centrosomes are 
microtubule organization centers in cells, and up to 30% of tumor endothelial cells often acquire 
excess (>2) centrosomes. Excess centrosomes are associated with aneuploidy and chromosome 
instability in tumor cells, but it is not known how untransformed endothelial cells respond to 
excess centrosomes. We found that the frequency of primary endothelial cells (EC) with excess 
centrosomes was quickly reduced in a p53-dependent manner. Excess centrosomes in EC were 
associated with p53 phosphorylation at Ser33, decreased cell proliferation and expression of 
senescence markers, but independent of DNA damage and apoptosis. EC with excess 
centrosomes in vascular sprouts also showed Ser33 p53 phosphorylation and expressed 
senescence markers. Our work shows that non-transformed EC respond differently to excess 
centrosomes than most tumor cells, and that they undergo senescence in vascular sprouts, 
suggesting that pathological outcomes of centrosome over-duplication depend on the 
transformation status of cells. 
                                                          
2
This chapter is adapted from a manuscript prepared for submission in 2016. I performed all of the 
experiments and wrote the first draft of the manuscript. Dr. Victoria Bautch edited and added to my 
original draft. Dr. Erich Kushner originally established the protocol for generating Tet-Plk4 HUVEC. 
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B. Introduction 
Cells rely on cell cycle to proliferate, ensuring an accurate inheritance of genetic 
information. An active eukaryotic cell cycle is divided into 4 phases: G1, S, G2 and M. Upon 
stress stimulation, cells can undergo cell cycle arrest as a self-protective mechanism to avoid cell 
death and to prevent genetic abnormalities [1,2]. Cells can be arrested at several checkpoints, but 
two major types of cell cycle arrest are the reversible quiescence and the permanent senescence, 
which share the same characteristic of no cell proliferation, but lead to dramatically different 
outcomes [3].   
Centrosomes, comprised of two barrel-shaped centrioles and surrounding pericentriolar 
material, are microtubule organizing centers (MTOC) and important for directed cell migration 
and chromosome segregation during mitosis [4,5]. Centrosome biogenesis is highly regulated to 
ensure that centrosomes are duplicated once and only once during each cell cycle [6]. Cells in G1 
have a single centrosome that is duplicated during S phase to form two centrosomes in G2, and 
these nucleate the bi-polar spindles at mitosis [7]. Loss of centrosome integrity induces p53-
dependent cell cycle arrest likely via senescence [8,9], indicating that cells have a surveillance 
mechanism that detects and responds to centrosome loss.  
Excess centrosomes are frequently found in tumor cells, where they are often associated 
with aneuploidy [10]. Tumor cells with excess centrosomes either form multi-polar spindles at 
mitosis that lead to gross aneuploidy, or cluster excess centrosomes to form bipolar spindles that 
are prone to merotely, the formation of inappropriate connections to spindles of individual 
chromosomes that can lead to subtle aneuploidy [11]. Although the process of centrosome 
clustering delays M phase in centrosome over-duplicated cells [12], the merotelic attachment 
cannot be detected by the spindle assembly checkpoint (SAC), and tumor cells with unresolved 
merotely progress through the cell cycle [13,14].  
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It was recently suggested that centrosome over-duplication leads to a p53-dependent 
checkpoint and growth arrest or apoptosis. Over-expression of a Kaposi’s sarcoma herpesviral 
protein in U2OS cells induced centrosome over-duplication and p53-dependent apoptosis [15], 
and excess centrosomes in immortalized RPE-1 cells prevented cell proliferation in a p53-
dependent manner [16]. Nevertheless, the existence of and the consequences of a p53-dependent 
“excess centrosome checkpoint” in primary cells are unknown.  Non-tumor endothelial cells (EC) 
derived from the tumor micro-environment have a high frequency of excess centrosomes, likely 
resulting in part from cell cycle alterations induced by elevated growth factor signaling [17-19]. 
However, how EC, which are untransformed, respond to excess centrosomes, and whether they 
have a surveillance mechanism for excess centrosomes remains unclear.  
Here we asked how primary EC respond to excess centrosomes. We found that EC with 
excess centrosomes were cell cycle arrested in a p53-dependent manner, and that excess 
centrosomes led to Ser33 but not Ser15 p53 phosphorylation, suggesting that the DNA damage 
response is not invoked. EC with excess centrosomes did not undergo apoptosis, but underwent 
p53-dependent senescence in culture and in vascular sprouts. Thus we reveal a previously 
unknown link between excess centrosomes and senescence through p53, and suggest that the 
response of untransformed cells with intact cell cycle regulation to excess centrosomes is 
senescence.   
 
C. Methods 
Cell culture 
Human umbilical vein endothelial cells (HUVEC, Lonza Group) were cultured in 
endothelial basal medium-2 (EBM-2, Lonza cc-3156) supplemented with the EGM-2 BulletKit 
(Lonza cc-3162). Tetracyclin-inducible Plk4-expressing HUVEC (Tet-Plk4 or Tet-Plk4
1-608
) 
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were generated as described [20]. Briefly, P2 HUVEC were infected with 500 μl/ml Plk4-
expressing Tet-ON lentiviruses [20] in 5 ml EGM-2 plus 1 μg/ml polybrene (Millipore TR-1003-
G) overnight at 37°C. Infected cells were incubated for 4d, followed with 2 μg/ml puromycin for 
selection. Viruses were produced by the UNC Lenti-shRNA Core Facility.  
Tet-Plk4 HUVEC were treated with 0.5-1 μg/ml doxycycline (DOX; Sigma D9891) for 
24h to induce centrosome over-duplication. p53 siRNA (Life technologies, 4427038-s605) 
transfection utilized RNAi Max (Life technologies, 13778-075) according to manufacturer’s 
protocols. Senescence was induced using H2O2 (Fisher scientific H325), etoposide (Sigma 
E1383), or hydroxyurea (Sigma H8627). Briefly, HUVEC were incubated with 100 μM H2O2 in 
EGM-2 for 2h/day for 3 consecutive days, and fixed/collected 2d post H2O2 treatment. HUVEC 
were incubated with etoposide (50 μM) or hydroxyurea (400 μM) for 6d, and fixed/collected 
immediately after treatment.   
 
Immunofluorescence  
HUVEC (in dishes or on gelatin-coated cover slips) were fixed in cold 100% MeOH for 
10 min, then stained as described previously [17]. Briefly, fixed cells were blocked in 5% bovine 
serum at RT for 1h, then incubated with primary antibodies at 4°C overnight. Cells were washed 
3X 5 min with PBS after primary antibodies, then incubated with secondary antibodies and the 
DNA dye DRAQ7 (1:1000, Abcam ab109202) for 2h at RT. Cells were washed 3X 10 min with 
PBS before mounting with VECTASHIELD mounting medium (Vector Laboratories H-1000). 
Both primary and secondary antibodies were diluted in 5% bovine serum in PBS. Images were 
acquired using an Olympus FV1200 confocal microscope. Immunofluorescence intensity was 
quantified using ImageJ. Primary antibodies were: anti-γ-tubulin (1:5000, Sigma T6557), anti-
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phospho-p53 (Ser33) (1:250, Cell signaling 2526), anti-cleaved-caspase3 (1:400, Cell signaling 
9664), anti-pericentrin (1:5000, Abcam 4448), anti-GLB1 (1:100, Abcam 139288), anti-
phospho-histone 3 (1:500, Cell signaling 3377), anti-H3K9Me3 (1:1000, Active Motif 39162), 
anti-γH2AX (1:500, Cell signaling 9718) and anti-BrdU (1:500, Abcam ab1893). Secondary 
antibodies were: goat-anti-mouse Alexa 488 (1:250, Invitrogen A11029), goat-anti-mouse Alexa 
594 (1:250, Invitrogen A11005), goat-anti-rabbit Alexa 488 (1:250, Invitrogen A11034) and 
goat-anti-rabbit Alexa 594 (1:250, Invitrogen A11037).  
 
BrdU labeling 
To detect cell proliferation, DOX-treated Tet-Plk4 HUVEC were incubated with 10 µM 
BrdU (Sigma B5002) for 24h. Cells were fixed in cold 100% MeOH for 10 min, and stained with 
anti-γ-tubulin antibodies as stated above. After γ-tubulin staining, cells were sequentially treated 
with 1N HCl on ice for 10 min, 2N HCl at RT for 10 min and phosphate/citric acid buffer (pH 
7.4) at RT for 10 min. Treated cells were re-blocked with 5% bovine serum, and stained with 
anti-γ-tubulin and anti-BrdU antibodies as stated above.  
 
Western Blots  
Western blot analysis was performed as previously described, with slight modifications 
[21]. Briefly, HUVEC lysates were collected using cold PBS, and lysed using RIPA buffer 
supplemented with protease inhibitors (Cell signaling 5871S). Proteins were separated on a 10% 
sodium dodecyl sulfate–polyacrylamide gel and transferred to a polyvinylidene fluoride 
membrane (GE Healthcare RPN303F), which was blocked in 5% BSA at RT for 1h, then 
incubated with primary antibodies at 4°C overnight. Membrane was washed 3X 5 min with TBS 
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containing 0.1% tween-20 (TBST), incubated with secondary antibodies at RT for 1h, washed 
with 0.1% TBST for 1h at RT, and imaged via Clarity Western ECL Substrate (Bio-Rad 170-
5061). Primary antibodies were: anti-p53 (1:1000, Abcam ab1101), anti-α-tubulin (1:15,000, 
Sigma T6199), anti-phospho-p53 (Ser33) (1:1000, Cell signaling 2526), anti-phospho-p53 
(Ser15) (1:1000, Cell signaling 9284), anti-p21 (1:1000, Cell signaling 2947), anti-β-actin 
(1:10,000, Cell signaling 3700), anti-caspase-3 (1:1000, Cell signaling 9662), anti-cleaved-
caspase3 (1:1000, Cell signaling 9664). Secondary antibodies were: HRP anti-rabbit (1:5000, 
Invitrogen G-21234), HRP anti-mouse (1:30,000, Invitrogen 81-6720).  
 
3D Sprouting Angiogenesis Assay 
The sprouting angiogenesis assay was performed as described [20,22]. DOX was added 
3d prior to putting HUVEC onto beads. To isolate Tet-Plk4 HUVEC from sprouts and beads, 
fibrin matrix was digested with 0.25% trypsin for approximately 1.5 h, until the fibrin matrix was 
completely liquefied. Isolated cells were re-plated on cover slips, and fixed after overnight 
incubation in EGM-2 medium. To determine excess centrosome frequency in sprouts in situ, Tet-
Plk4 HUVEC were infected with 100 μl/ml lentiviruses expressing a centrin-GFP fusion protein 
[20] overnight during DOX treatment. The number of centrosomes in 3D sprouts was determined 
using an Olympus FV1200 confocal microscope with a 40X oil objective.  
To label cells with BrdU in sprouts, 10 μM BrdU in EGM-2 was added to wells 2d post 
embedding of HUVEC-coated beads. Cells were incubated with BrdU for 8d, then recovered by 
plasmin digestion. Briefly, the fibroblast layer was removed by 0.25% trypsin digestion, after 
which fibrin was then incubated with 1 mg/ml plasmin (Sigma P1867) for approximately 1h, 
until the fibrin matrix was completely liquefied. Cytodex beads were settled and removed from 
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supernatant, which was then centrifuged to collect recovered EC. The cell pellet was 
resuspended, a single cell suspension was generated by 0.05% trypsin digestion for 1 min, and 
EC were plated onto cover slips overnight before fixation and staining.  
 
Senescence β-Galactosidase Staining Assay 
The senescence β-Galactosidase (SA-β-gal) assay was performed according to 
manufacturer’s directions (Cell Signaling 9860). Briefly, fixed cells were incubated overnight in 
1 ml staining solution with X-gal. Cells in fibrin were fixed with 2% paraformaldehyde (PFA) 
for 15 min, and incubated in 500 μl staining solution for 1-2d. Images were acquired using an 
Olympus IX50 microscope with a bright field filter. To correlate centrosome status and SA-β-gal, 
centrin-GFP-expressing EC were examined under an Olympus FV1200 confocal microscope 
with a 40X oil objective to identify cells with centrosome over-duplication. Wells were then 
incubated with X-gal substrate, and the SA-β-gal staining of pre-identified centrosome over-
duplicated cells was examined under an Olympus IX50 microscope under bright field. 
Centrosome images and SA-β-gal stained images were overlaid using ImageJ. 
 
Software and Statistical Analysis 
The Student’s t-test and Χ2 test were used to determine statistical significance in cases 
with 3 repeats and 2 repeats, respectively. Error bars represent standard deviations from the mean 
from independent experiments. Prism Graphpad was used to perform statistical analysis and 
generate graphs. ImageJ and R3.2.2 software were used to analyze H3K9Me3 staining patterns.  
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D. Results 
Excess Centrosome Frequency Is Not Maintained in EC 
We developed a tetracycline-inducible Plk4 expression system (Tet-Plk4) in HUVEC to 
conditionally induce centrosome over-duplication (Fig 3.1A) [20]. γ-tubulin was used to label 
centrosomes, and EC with more than 2 centrosomes (>2) were considered centrosome over-
duplicated (Fig 3.1B) [20]. The γ-tubulin signal was confirmed as centrosome-specific by co-
labeling EC with another centrosome-localized protein, centrin tagged with GFP, which showed 
strong overlap with γ-tubulin (Supp. Fig 3.1). Treatment of Tet-Plk4 HUVEC with doxycycline 
(DOX) resulted in a significant increase in the percentage of EC with excess centrosomes 
compared to controls (Fig 3.1C).  
Next we asked whether EC maintain DOX-induced excess centrosomes over time. Tet-
Plk4 HUVEC were treated with DOX for 24h, the DOX was removed, and EC were analyzed for 
centrosome numbers relative to elapsed time (Fig 3.1D). At day 0, about 25% of treated EC had 
excess centrosomes, and there was a time-dependent decrease in the frequency of EC with excess 
centrosomes from days 2 to 6 (Fig 3.1E). These results in primary human EC are consistent with 
previous data in mouse tumor EC [17], suggesting that centrosome over-duplication either leads 
to EC loss or reduces their competitive advantage in culture relative to non-over-duplicated EC.  
 
Decrease of Excess Centrosome Frequency in EC Is p53-Dependent 
Loss of centrosome integrity leads to p53 phosphorylation at Ser33 [8], so we tested 
whether centrosome over-duplication has similar effects on p53 phosphorylation. We found that 
DOX treatment elevated levels of p53 protein and dramatically increased p53 phosphorylation on 
Ser33 (Fig 3.2A). Consistent with activated p53, levels of the p53 target p21, a protein that 
blocks the cell cycle by inhibiting cyclin-dependent kinases [23,24], were also elevated (Fig 
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3.2A). The upregulation of p53 levels by excess centrosomes in EC is consistent with previous 
reports showing that Plk4 over-expression elevates p53 in RPE-1 cells [25]. To test the 
association between centrosome over-duplication and p53 phosphorylation, we stained cells with 
γ-tubulin and phosphorylated p53 (pp53) (S33) after DOX treatment to assess pp53 (S33) levels 
on a per cell basis (Fig 3.2B). We found that significantly more centrosome over-duplicated EC 
were positive for pp53 staining than EC with normal centrosome numbers (Fig 3.2C), and the 
intensity of pp53 (S33) staining was significantly higher in EC with excess centrosomes (Fig 
3.2D). To confirm that the effects on p53 phosphorylation resulted from centrosome over-
duplication and not some other aspect of Plk4 activity, we conditionally over-expressed Plk4
1-608
, 
a truncated Plk4 protein that retains its kinase activity without inducing centrosome over-
duplication [26]. After DOX treatment, pp53 (S33) levels in Tet-Plk4 HUVEC with 1-2 
centrosomes were similar to that in Tet-Plk4
1-608
 HUVEC, but remarkably lower than that in 
centrosome over-duplicated Tet-Plk4 HUVEC, indicating that bona fida centrosome over-
duplication instead of Plk4 kinase activity induces p53 phosphorylation (Supp. Fig 3.2A). 
Overall these results demonstrate that excess centrosomes lead to increased p53 phosphorylation 
at S33.  
Because of the correlation between centrosome over-duplication and p53 phosphorylation, 
we hypothesized that the decrease in EC with excess centrosomes over time is dependent on p53. 
Knockdown of p53 via siRNA maintained excess centrosome frequency for several days as 
control EC frequencies dropped (Fig 3.2E). By day 6, the excess centrosome percentage in p53 
siRNA-treated cells had decreased to that of the controls (Fig 3.2E), coinciding with the 
recovery of p53 levels after knockdown (Supp. Fig 3.2B). These results demonstrate that p53 is 
required for the decrease in EC with centrosome over-duplication.  
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Excess Centrosomes Do Not Induce DNA Damage or Apoptosis 
Excess centrosomes promote DNA segregation errors, which result in DNA damage and 
p53 activation [12,27]. A well-characterized output of DNA damage is p53 phosphorylation at 
Ser15 [28]. To test if excess centrosomes induced DNA damage, we determined the levels of 
pp53 (Ser15) in DOX-treated Tet-Plk4 HUVEC. DOX treatment significantly induced p53 
phosphorylation at Ser33 but not at Ser15, indicating that centrosome over-duplication does not 
induce a p53-mediated DNA damage response (Fig 3.3A). Using another marker of DNA 
damage, γH2AX [29], we found that UV treatment, but not centrosome over-duplication, 
significantly induced γH2AX levels (Fig 3.3B-C). These results suggest that excess centrosomes 
induce p53 phosphorylation independent of DNA damage pathways.  
p53 activation promotes apoptosis [30], and excess centrosomes may induce p53-driven 
apoptosis [15], so we asked whether the decrease in EC with excess centrosomes resulted from 
p53-induced apoptosis (Fig 3.1E). To test this, we measured the levels of cleaved caspase-3, 
which is the activated form of caspase-3 during apoptosis [31]. While UV treatment of HUVEC 
induced caspase-3 cleavage, DOX treatment did not lead to caspase activation (Fig 3.3D). 
Immunofluorescence staining for cleaved caspase-3 confirmed these results (Fig 3.3E), 
suggesting that excess centrosomes do not induce apoptosis. 
 
Excess Centrosomes Induce p53-Dependent Senescence 
p53 activation can also promote permanent cell cycle arrest, or senescence [32,33]. To 
examine whether EC with excess centrosomes were proliferative, we assessed 
bromodeoxyuridine (BrdU) incorporation (Fig 3.4A). Approximately 80% of control EC (1-2 
centrosomes) were BrdU+, while only about 30% of centrosome over-duplicated EC were 
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BrdU+ (Fig 3.4A-B). Strikingly, knockdown of p53 completely rescued the frequency of BrdU+ 
EC with centrosome over-duplication (Fig 3.4B), suggesting that centrosome over-duplication 
leads to p53-dependent cell cycle arrest in EC. We also compared the proliferation of DOX-
treated Tet-Plk4
1-608
 and Tet-Plk4 HUVEC with 1-2 centrosomes, and found no differences 
(Supp. Fig 3.3A), indicating that centrosome over-duplication, not Plk4 kinase activity, induces 
cell cycle arrest. Overall, these results show that centrosome over-duplication leads to p53-
dependent cell cycle arrest in EC. 
Senescence-associated beta-galactosidase (SA-β-gal) activity increases as cells become 
senescent [34]. To determine if centrosome over-duplication causes senescence in EC, we treated 
Tet-PLK4 HUVEC with DOX and assayed for SA-β-gal (Fig 3.4C). DOX treatment led to a 
greater than 2-fold increase in the percentage of SA-β-gal positive EC compared to controls, and 
p53 knockdown blocked the SA-β-gal induction (Fig 3.4D). We further confirmed this result by 
staining and quantifying the levels of galactosidase-beta 1(GLB1), which is the enzyme 
responsible for SA-β-gal activity [35], and found significantly increased levels of GLB1 in 
centrosome over-duplicated EC, and this increase was blocked by p53 knockdown (Fig 3.4E-F). 
Overall, these results demonstrate that centrosome over-duplication in EC significantly induces 
the expression of senescence markers in a p53-dependent manner, suggesting that excess 
centrosomes trigger senescence in primary EC.  
Senescent cells can have senescence-associated heterochromatin foci (SAHF), and tri-
methylation of lysine 9 on histone 3 (H3K9Me3) is a common marker for heterochromatin 
[36,37]. We tested whether centrosome over-duplicated EC have SAHF by staining for 
H3K9Me3, using several senescence-inducing chemical agents as positive controls [38-40]. 
H3K9Me3 staining patterns in senescent cells were more uniformly distributed compared to 
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vehicle-treated cells (Supp. Fig 3.3B-C, E). To quantitatively determine the H3K9Me3 
distribution, we measured the H3K9Me3 fluorescence intensity at each pixel in the nucleus, and 
normalized it to the mean H3K9Me3 intensity in its respective nucleus. The percentage of pixels 
with intensity/mean value >1.5 or <0.5 in senescent nuclei is significantly lower than that in 
control cells (Supp. Fig 3.3C-D), demonstrating that H3K9Me3 is more uniformly distributed in 
senescent EC nuclei. We next performed similar measurements in DOX-treated Tet-Plk4 
HUVEC, and found that the H3K9Me3 distribution in centrosome over-duplicated EC is similar 
to that seen in senescent cells (Supp. Fig 3.3F), indicating a senescence phenotype. Collectively, 
these results show that excess centrosomes lead to a p53-dependent senescence-like phenotype in 
EC.  
 
Excess Centrosomes Induce p53 Phosphorylation and Senescence in EC in 3D 
We next wanted to know whether the link between excess centrosomes and EC 
senescence held in a more physiological setting. We used a sprouting angiogenesis assay in 
which HUVEC extend and form lumenized sprouts in a fibrin matrix [22]. DOX treatment did 
not perturb the sprouting behavior of Tet-Plk4 HUVEC (Fig 3.5A). Interestingly, EC maintained 
a higher percentage of excess centrosomes over a longer period of time in 3D compared with 2D. 
This effect was associated with differences in cell proliferation as read out by staining for the 
mitotic marker phospho-histone H3 (Supp. Fig 3.4A-C). To detect p53 activation in 3D sprouts, 
we visualized centrosomes with centrin-GFP [20], then stained cells for pp53 (S33). Consistent 
with our 2D data, we found that centrosome over-duplicated EC had significantly higher levels 
of pp53 (S33) in 3D (Fig 3.5B-C). BrdU incorporation analysis showed that significantly fewer 
EC with excess centrosomes were BrdU+ compared to EC with normal centrosome numbers in 
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3D (Fig 3.5D). We next examined EC in sprouts for the senescence marker SA-β-gal, and found 
that DOX treatment led to a 3-fold increase in the percentage of SA-β-gal positive cells 
compared to controls (Fig 3.5E-F). To correlate centrosome over-duplication and SA-β-gal, EC 
centrosomes were visualized with centrin-GFP. SA-β-gal staining was largely confined to EC 
with excess centrosomes in sprouts (Fig 3.5G). Overall, these results suggest that excess 
centrosomes induce p53-dependent senescence in sprouting EC. 
 
E. DISCUSSION 
EC do not maintain a high frequency of centrosome over-duplication in culture, 
indicating that excess centrosomes somehow compromise the EC cell cycle [17]. Here we show 
that excess centrosomes induce p53 phosphorylation at Ser33, and loss of p53 allows EC to 
maintain a high frequency of excess centrosomes. Excess centrosome-induced p53 activation 
was independent of DNA damage, and did not induce apoptosis, but rather induced a senescence-
like phenotype in 2D and in 3D sprouts. Thus excess centrosomes induce p53-dependent 
senescence without DNA damage in primary EC, revealing a novel effect of excess centrosomes 
may depend on whether cells have intact cell-cycle checkpoints. 
It has been unclear whether cells have a surveillance mechanism for centrosome over-
duplication. A proposed p53-dependent “tetraploidy checkpoint” downstream of drug-induced 
cytokinesis failure and subsequent excess centrosomes was later found to be a side effect of drug 
overdose [41,42]. Moreover, cells with excess centrosomes often cluster centrosomes and 
undergo bipolar cell divisions to produce viable progeny [12,20], indicating that in some 
scenarios cells may tolerate centrosome over-duplication and survive. This centrosome clustering 
mechanism is frequently observed in a variety of tumor cells [43,44], providing an explanation 
for a high frequency of excess centrosomes in these cells [11]. Our work shows that primary 
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human EC, unlike most tumor cells, undergo p53-dependent senescence downstream of excess 
centrosomes both in 2D culture and in 3D sprouts, showing that primary EC have a surveillance 
mechanism for centrosome over-duplication. This is consistent with a recent report showing that 
immortalized RPE-1 cells with excess centrosomes have increased total p53 levels [16].  
Cell division after centrosome over-duplication can be deleterious to cells. Excess 
centrosomes often lead to multipolar spindle formation, which induces gross aneuploidy or cell 
death [11,12]. Alternatively, clustering of excess centrosomes produces DNA damage or 
aneuploidy and chromosome instability resulting from merotelic attachments [27], [12]. Here we 
show the existence of a p53-dependent “excess centrosome checkpoint” in primary cells that 
leads to senescence. We posit that in primary cells with excess centrosomes, this checkpoint 
prevents cell death and may maintain the integrity of blood vessels. Senescence is also predicted 
to prevent mitosis-associated defects such as aneuploidy and chromosome instability, and may 
be a mechanism to prevent transformation-inducing mutations downstream of excess 
centrosomes. The potential lack of this checkpoint in tumor cells may result in different 
outcomes for tumor cells with excess centrosomes. 
Our finding that EC with excess centrosomes can undergo senescence in 3D sprouts may 
be relevant in the tumor microenvironment, since up to 30% of tumor EC have over-duplicated 
centrosomes [17,18]. Tumor vessels are disorganized, tortuous, leaky, and insufficiently perfused 
[45,46], and excess centrosome-induced senescence in tumor EC may contribute to these 
abnormalities. For example, tumor EC have altered migration properties [17,20] and may have 
increased secretion of IL-1, a hallmark of senescent cells [47,48]. This work describes a novel 
checkpoint that connects centrosome over-duplication, p53 activation and senescence. We think 
that primary cells, unlike tumor cells, maintain an intact checkpoint for centrosome over-
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duplication. This may be a general defense mechanism allowing primary cell to survive while 
avoiding mutations leading to transformation.  
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F. Figures 
Figure 3.1. Excess centrosome frequency is not maintained in EC. 
(A) Schematic representation of tetracycline-inducible Plk4 (Tet-Plk4) in HUVEC. (B) 
Representative images of DOX-induced centrosome over-duplication in Tet-Plk4 HUVEC. (C) 
Frequency of excess centrosomes in indicated EC 2d post DOX treatment. (D) Experimental 
timeline; DOX added at day -3 for 24h. (E) Percent centrosome over-duplication in Tet-Plk4 
HUVEC on indicated days. Statistics: two-tailed Student’s t test. Error bars, standard deviation 
from mean. *, p<0.05; ns, not significant. 
  
83 
 
  
84 
Figure 3.2. Decrease in excess centrosome frequency is p53-dependent.  
(A) Western blot of phosphorylated p53 at Ser 33(pp53(S33)), total p53 and p21 in DOX-treated 
Tet-Plk4 HUVEC on d0. Normalized densitometry values are below each band. pp53(S33) 
normalized to total p53; total p53 and p21 normalized to α-tubulin. (B) Representative images of 
DOX-treated tet-Plk4 HUVEC on d0 stained for pp53(S33) (red), γ-tubulin (green) and DRAQ7 
(blue). Yellow arrows, nuclei of EC with excess centrosomes. (C) Percent pp53+ cells in Tet-
Plk4 HUVEC with 1-2 (n=524) or >2 (n=313) centrosomes on d0. (D) Log plot of mean 
fluorescence intensity of pp53(S33) in Tet-Plk4 HUVEC with 1-2 or >2 centrosomes on d0. (E) 
Percent excess centrosomes at indicated days in DOX-treated Tet-Plk4 HUVEC. Cells were 
transfected with control siRNA or p53 siRNA on d-1. Statistics: two-tailed Student’s t test. Error 
bars, standard deviation from mean. *, p<0.05; ***, p<0.01; ****, p<0.0001; ns, not significant.  
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Figure 3.3. Excess centrosomes do not induce DNA damage or apoptosis.  
(A) Western blot of p53 phosphorylation at Ser15 and Ser33. Tet-Plk4 HUVEC were DOX-
treated on d-3 and collected on d0, and wild-type (WT) HUVEC were treated with UV. (B) 
Representative images showing γH2AX staining in Tet-Plk4 HUVEC with different centrosome 
numbers and WT HUVEC treated with UV. (C) Mean fluorescence intensity of γH2AX in 
indicated cells. (D) Western blot of full length and cleaved caspase-3 levels in Tet-Plk4 HUVEC 
treated with DOX or WT HUVEC treated with UV. (E) Representative images of cleaved 
caspase-3 staining in Tet-Plk4 HUVEC with >2 centrosomes or UV-treated WT HUVEC. 
Statistics, two-tailed Student’s t test. Error bars, standard deviation from mean. ***, p<0.001; ns, 
not significant. 
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Figure 3.4. Excess centrosomes induce p53-dependent senescence.  
(A) Representative image of DOX-treated Tet-Plk4 HUVEC stained for BrdU (red), centrosome 
(green), and DRAQ7 (blue). (B) Percent BrdU+ cells in control siRNA-treated (left) and p53 
siRNA-treated (right) Tet-Plk4 HUVEC with indicated centrosome numbers. (C) Cytochemical 
staining of SA-β-gal in DOX-treated Tet-Plk4 HUVEC on d2. Black arrows, SA-β-gal+ EC. (D) 
Relative percent of SA-β-gal+ Tet-Plk4 HUVEC on d2. Results are fold change, with each value 
normalized to its respective control (control siRNA-treated d2 Tet-Plk4 HUVEC without DOX 
exposure). (E) Representative images of DOX-treated Tet-Plk4 HUVEC stained for GLB1 and 
pericentrin on d2. (F) Mean fluorescence intensity of GLB1 in control-siRNA treated (left) and 
p53-siRNA treated (right) Tet-Plk4 HUVEC with indicated centrosome numbers. Statistics, two-
tailed Student’s t test. Error bars, standard deviation from mean. *, p<0.05; **, p<0.01; ns, not 
significant. 
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Figure 3.5. Excess centrosomes induce senescence markers in EC in sprouts.  
(A) Representative images of sprouting EC in 3D. Tet-Plk4 HUVEC were treated with (+DOX, 
right) or without (-DOX, left) DOX on d-1 before embedding on d0, and stained with phalloidin. 
Z-stacks are depth-coded. (B) Representative images of sprout EC stained for phospho-p53 
(Ser33) (pp53(S33), red) and labeled with centrin-GFP (green, centrosomes) in 3D. (C) Mean 
fluorescence intensity of phospho-p53 (Ser33) (pp53(S33)) in EC in sprouts. (D) Percent BrdU+ 
cells in Tet-Plk4 HUVEC recovered from 3D sprouts on d9. (E) Cytochemical staining of SA-β-
gal in sprouting angiogenesis assay. Tet-Plk4 HUVEC were treated with DOX (+DOX) or not (-
DOX). Black arrows; SA-β-gal+ EC in sprouts. (F) Relative percent SA-β-gal+ in sprouting Tet-
Plk4 HUVEC with indicated treatments. Results are fold change, with each value normalized to 
its respective control (Tet-Plk4 HUVEC sprouts without DOX treatment). (G) Representative 
images of SA-β-gal+ EC coincident with EC with excess centrosomes. Centrosomes labeled with 
centrin-GFP. Statistics, two-tailed Student’s t test (C, F), Χ2 test (D). Error bars, standard 
deviation from mean. *, p<0.05; **, p<0.01. 
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Supplementary Figure 3.1. Colocalization of centrin-GFP and γ-tubulin. 
A representative image of Tet-Plk4 HUVEC with centrin-GFP (green) and γ-tubulin staining 
(red). Nucleus is stained with DRAQ7 (blue). 
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Supplementary Figure 3.2. Centrosome over-duplication instead of Plk4 kinase activity 
induces p53 phosphorylation. 
(A) Mean fluorescence intensity of phospho-p53 (S33) (pp53 (S33)) in DOX-treated Tet-Plk4 or 
Tet-Plk4
1-608
 HUVEC on d0.  (B) Western blot of p53 in Tet-Plk4 HUVEC treated with control 
or p53 siRNA and collected on indicated days post-treatment. Statistics, two-tailed Student’s t 
test. Error bars, standard deviation from mean. **, p<0.01. ****, p<0.0001.   
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Supplementary Figure 3.3. EC with excess centrosomes exhibit similar H3K9Me3 staining 
pattern with senescent EC. 
(A) Percent BrdU+ cells in DOX-treated Tet-Plk4
1-608
 or Tet-Plk4 HUVEC with 1-2 centrosomes. 
(B) Representative images of indicated chemical-treated HUVEC stained for SA-β-gal and 
H3K9Me3. Yellow dashed lines, path of line scans shown in (C, E). (C). Line scan of H3K9Me3 
intensity of HUVEC with indicated treatments, normalized to respective means. (D) Percent 
pixels with intensity/mean >1.5 or <0.5 in each nucleus in HUVEC treated with vehicle or H2O2. 
(E) Line scan of H3K9Me3 intensity of HUVEC with indicated treatments, normalized to 
respective means. (F) Percent pixels with intensity/mean >1.5 or <0.5 in each nucleus in HUVEC 
treated with vehicle, etoposide or hydroxyurea (HU). (G) Representative images of DOX-treated 
Tet-Plk4 HUVEC stained for H3K9Me3 on d2. Yellow dashed lines, path of line scans shown in 
(H). (H) Line scan of H3K9Me3 intensity of HUVEC with indicated treatments, normalized to 
respective means. (I) Percent pixels with intensity/mean >1.5 or <0.5 in each nucleus in Tet-Plk4 
HUVEC with 1-2 or >2 centrosomes. Statistics, two-tailed Student’s t test. Error bars, standard 
deviation from mean. **, p<0.01; ***, p<0.001; ****, p<0.0001; ns, not significant. 
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Supplementary Figure 3.4. EC better maintain excess centrosome percentage in 3D sprouts 
than 2D. 
(A) Percent excess centrosomes in Tet-Plk4 HUVEC in 2D or 3D (total) at indicated days. Cells 
in 3D were recovered from fibrin matrix by prolonged trypsin digestion (see methods). (B) 
Percent excess centrosomes in Tet-Plk4 HUVEC in 2D or 3D (sprouts) at indicated days. Excess 
centrosome percentage in 3D was determined via examining centrin-GFP signal in situ (see 
methods). (C) Percent phospho-histone 3+ (PH3+) cells in Tet-Plk4 HUVEC in 2D or 3D. 
Statistics, two-tailed Student’s t test. Error bars, standard deviation from mean. ****, p<0.001. 
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CHAPTER IV-Cell-Autonomous Effects of p53 Loss on Angiogenesis
3
 
A. Introduction 
Blood vessel formation is dependent on angiogenesis, the process where new vessels 
sprout and extend from pre-existing ones. Angiogenesis is a highly coordinated program 
involving a series of cell migration and cell proliferation events in endothelial cells (EC), an 
essential component of blood vessels [1]. Many signaling pathways, such as vascular endothelial 
growth factor (VEGF-A) and NOTCH, participate in the regulation of angiogenesis, which is 
normally inactive in adults, but can be re-activated in certain situations such as wound healing or 
tumor progression [1,2]. Tumors are usually highly vascularized, and require tumor blood 
vessels for oxygen and nutrients after reaching the size of 2 mm in diameter [3]. Tumor 
vasculature is morphologically and functionally abnormal with tortuosity, leakiness and uneven 
lumens, contributing to tumor dissemination [4]. It is not completely understood how tumor 
vessels acquire these abnormalities, but the tumor micro-environment is believed to contribute to 
the defects. 
p53 is a well-known cell cycle regulatory protein that senses and responds to cell stress 
by initiating downstream gene expression to either inhibit the cell cycle or induce cell death [5]. 
It is a tumor suppressor that is mutated in about half of identified tumors, indicating its critical 
role in controlling tumor progression. In addition to regulating cell cycle, p53 inhibits cell 
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performed the random migration assay in HUVEC treated with p53 shRNA. 
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migration in mouse embryonic fibroblasts [6-8], therefore likely limiting tumor cell invasion and 
metastasis. 
p53 also regulates tumor angiogenesis in a cell non-autonomous manner. Clinical data 
show that tumors with mutated p53 are more vascularized than those with wild-type p53, and 
correlate with poor prognosis [9]. Tumor cells secrete many angiogenic factors, such as vascular 
endothelial growth factor-A (VEGF-A) and basic fibroblast growth factor (bFGF), into the tumor 
microenvironment to promote angiogenesis, and p53 can repress the expression of these factors 
[10]. In addition, p53 upregulates the release of a variety of antiangiogenic proteins from tumor 
cells, such as thromobospondin-1 (TSP-1) [11,12]. Therefore p53 mutations in tumor cells 
promote angiogenesis in a cell non-autonomous manner. However, the EC-autonomous effects 
of p53 in angiogenesis remain elusive.  
 Here we present the novel findings about EC-autonomous roles of p53 in angiogenesis. 
We found that p53 inhibits sprouting, EC migration and EC proliferation in vitro. Contradictory 
to the in vitro results, p53 global knockout (KO) mice had decreased angiogenesis in vivo, and 
EC-selective p53 KO did not have significant effects on angiogenesis in vivo.  
 
B. Materials and Methods 
Cell culture  
Human umbilical vein endothelial cells (HUVEC) were cultured in endothelial cell 
growth media-2 (EGM-2, Lonza cc-3162). Tetracyclin-inducible Polo-like kinase 4 (Tet-Plk4) 
HUVEC were made as previously described [13]. Doxycycline (DOX; Sigma D9891) was added 
at 1 μg/ml in EGM-2 to induce centrosome over-duplication in Tet-Plk4 HUVEC. RNAi Max 
transfection agent (Life technologies 13778-075) was used to transfect HUVEC with non-
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targeting (Life technologies 4390847) or p53 siRNA (Life technologies 4427038-s605) 
according to the manufacturer protocols. Control or p53 shRNA (Open Biosystems, clone ID: 
V3LHS_333920) were introduced into HUVEC via infection of lentiviruses purchased from the 
UNC Lenti-shRNA Core Facility.  
 
Sprouting angiogenesis assay 
Sprouting angiogenesis assays were performed as previously described with slight 
modifications [14]. Briefly, Tet-Plk4 HUVEC were mixed with Cytodex microcarrier beads, 
incubated and agitated at a 20-min interval for 4 hours. Beads coated with HUVEC were plated 
on a 6-cm dish, resuspended in 2 mg/ml fibrinogen (Fisher Scientific 820224) in PBS the next 
day, and embedded in a fibrin matrix by adding thrombin (Sigma T7201). Human lung 
fibroblasts (Lonza cc2512) were plated on top of fibrin, and EGM-2 medium was changed every 
other day. HUVEC cells were cultured in fibrin for 6 days, fixed with 4% paraformaldehyde, 
stained with phalloidin (Invitrogen A-12381), and imaged using an Olympus FV1200 
microscope with a 10X objective. Images were analyzed using ImageJ.   
 
Cell migration assay 
Random cell migration assay were performed as previously described [15]. HUVEC, 
infected with shRNA viruses or transfected with siRNA, were seeded on a glass-bottom dish 
coated with 2 μg/ml fibronectin (Sigma F2006). Cells were live-imaged at 5 min intervals for 3 
hours using an Olympus FV1200 microscope with a 20X objective. Images were acquired with a 
DIC filter, and cell tracks were analyzed with mTrackJ software (Meijering Laboratory). 
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Mouse strains and tissue preparations 
All experiments involving animals were performed with the approval of the University of 
North Carolina, Chapel Hill Institutional Animal Care and Use Committee. The p53
 
KO mice 
were purchased from The Jackson Laboratory (#002101), and retinas were harvested at P4 or P5. 
To induce EC-selective p53 KO, p53 flox mice (p53
fl/fl
; JAX #008462) were mated to Cdh5-
Cre
ERT2+/-
 mice (JAX #006137), and tamoxifen was injected at a dose of 0.25 mg/mL at P1 and 
P2, with retinas harvested at P5. Retinas were fixed, processed and stained with Alexa Fluor 488-
conjugated isolectin (Invitrogen I21411) as previously described [16]. Images were acquired 
using an Olympus FV1200 microscope with a 10X objective, and analyzed using ImageJ.  
 
C. Results 
Down-regulation of p53 in EC induces angiogenesis in vitro 
To determine the EC autonomous effects of p53 on angiogenesis, we reduced p53 levels 
in EC via siRNA knock-down (KD) and performed 3D sprouting angiogenesis assays. p53 
siRNA-treated HUVEC had increased sprouting, demonstrated by more and longer sprouts than 
controls (Fig. 4.1A-C). We previously showed that excess centrosomes in EC compromise 
angiogenesis [13]. To determine if p53 knockdown rescues excess centrosomes-induced 
angiogenesis defects, Tet-Plk4 HUVEC, which lead to centrosome over-duplication with 
doxycycline (DOX) treatment, were transfected with p53 siRNA. DOX treatment did not 
significantly reduce sprout number/bead or sprout length (Fig. 4.1D-E), which is not consistent 
with previous results probably due to different methods [13]. However, Tet-Plk4 HUVEC treated 
with p53 siRNA had more and longer sprouts than EC with control siRNA (Fig. 4.1D-E). We 
also validated our finding with p53 shRNA, which led to more and longer sprouts compared with 
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control (Fig. 4.1F). Overall, we find that knockdown of p53 in EC induces sprouting, suggesting 
a cell-autonomous effect of p53 on angiogenesis.  
 
Down-regulation of p53 promotes EC migration and proliferation 
Angiogenesis is dependent on cell migration, and p53 inhibits cell migration in mouse 
embryonic fibroblasts [6]. To understand the mechanisms of p53 loss-induced sprouting, we first 
investigated the effects of p53 loss on EC migration. Down-regulation of p53 by shRNA 
increased the migration distance in random migration assays (Fig. 4.2A-B). Similarly, p53 
siRNA treatment significantly induced cell migration compared with control siRNA (Fig. 4.2C), 
indicating that p53 knockdown promotes sprouting by increasing cell migration. p53 is also 
known as a critical cell cycle suppressor [5]. To determine if cell proliferation contributes to p53 
loss-induced sprouting, we analyzed HUVEC growth curves and found that HUVEC treated with 
p53 siRNA had increased growth relative to controls (Fig. 4.2D). Collectively, these results 
suggest that loss of p53 promotes sprouting by increasing cell migration and proliferation.  
 
Knockout of p53 does not promote angiogenesis in vivo 
To determine if loss of p53 induces angiogenesis in vivo, we examined sprouting and 
branching in postnatal mouse retina vessels (Fig 4.3A). We analyzed sprout number at the 
vascular front and the branch number near the vascular front in wild-type (WT, p53
+/+
), p53 
heterozygous (p53
+/-
) and p53 KO (p53
-/-
) B6 mice. We found that the sprouting and branching 
parameters in p53
+/-
 mice retina were not significantly different from those in WT retina, while 
P5 p53
-/-
 retina had less sprouts/mm at the front compared to the P5 p53
+/- 
retinas (Fig 4.3B-C). 
In addition, P4 and P5 p53
-/-
 retinas had decreased branch numbers compared with P4 and P5 
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p53
+/- 
retinas, respectively (Fig 4.3D-E). These results indicate that loss of p53 inhibits 
angiogenesis in vivo in the mouse retina, which is not consistent with our in vitro data.  
We reasoned that loss of p53 in other cell types besides EC led to the decreased 
angiogenesis in vivo. To test this, we generated EC-selective p53 conditional KO mice by 
crossing Cdh5-Cre
ERT2+/-
 mice with p53
fl/fl 
mice, and injected tamoxifen at P1 and P2 to induce 
recombination-mediated p53 excision in EC. EC-selective p53 KO did not have significant 
effects on the retinal vasculature at P5, indicating that EC-autonomous KO of p53 do not affect 
EC angiogenesis in vivo (Fig 4.3F-G). 
 
D. Discussion 
Mutated p53 induces angiogenesis in a cell non-autonomous manner [10], but it is not 
known whether mutated p53 in EC have cell-autonomous effects on angiogenesis. Here we show 
that knockdown of p53 in EC induces sprouting in vitro, likely through increased EC migration 
and EC proliferation. Contradictory to the in vitro results, global p53 global deletion inhibited 
angiogenesis in vivo, and EC-selective p53 KO did not have apparent effects on retinal 
angiogenesis in vivo.  
Tumor vessels, although morphologically and phenotypically abnormal, are required for 
tumor growth, and tumor angiogenesis is considered a hallmark of cancer [17].  One mechanism 
for the high vascularization of tumors may depend on lost/mutated p53, which happens in about 
50% of tumors and contributes to tumor vascularization in a cell non-autonomous manner 
[10,18]. Tumor EC were considered genetically normal until recent evidence showed that p53 
signaling is also compromised in tumor stromal cells, including tumor EC [19]. However, the 
effects of compromised p53 in tumor EC are unknown. Here we show that knockdown of p53 in 
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EC promotes angiogenic sprouting in vitro, indicating that compromised p53 signaling in tumor 
EC may contribute to tumor angiogenesis in a cell autonomous manner.  
We found that p53 knockdown promotes EC migration and proliferation, two essential 
components of angiogenesis. These results are consistent with previous findings that loss of p53 
increases cell migration in mouse embryonic fibroblasts (MEF) [6-8], and the fact that p53 
inhibits cell cycle [5]. The next step will be focused on understanding the mechanisms of p53 
loss-induced EC migration and proliferation in EC. p53 loss-induced increased MEF migration is 
dependent on increased Rho signaling and decreased cell-cell junction [8], and it is likely that the 
same mechanisms exist in EC.  
Although we found increased sprouting induced by p53 knockdown in vitro, we did not 
identify these effects of p53 in vivo. p53 global KO mice had reduced postnatal retinal 
angiogenesis compared to controls, and EC-selective p53 deletion mice were not different from 
controls in retinal angiogenesis. It is possible that retina angiogenesis reflects a distinct 
physiological developmental process that differs from tumor. To test this hypothesis, we will 
cross EC-selective p53 KO mice to a transgenic mouse that develops spontaneous tumors, such 
as MMTV-PyMT mice which develop spontaneous breast tumors, and examine tumor vessel 
density. We hypothesize to see higher vascularization in EC-selective p53 KO tumors.   
In summary, we found that loss of p53 induces sprouting in vitro, likely via increased EC 
migration and proliferation in a cell autonomous manner, but does not affect retinal angiogenesis 
in vivo when deleted in EC. Future work will focus on understanding the mechanisms. 
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E. Figures 
Figure 4.1. Down-regulation of p53 in EC induces angiogenesis in vitro.  
(A) Representative images of sprouting HUVEC. HUVEC were transfected with control siRNA 
or p53 siRNA. Z-stacks are depth-coded. (B) Mean sprout number/bead of wild-type (WT) 
HUVEC treated with control or p53 siRNA. (C) Average length of WT HUVEC sprout treated 
with control or p53 siRNA. (D) Mean sprout number/bead of Tet-Plk4 HUVEC treated as 
indicated. (E) Average length of Tet-Plk4 HUVEC sprout treated as indicated. (F) Representative 
images of sprouting WT HUVEC treated with control shRNA or p53 shRNA (p53#20). Statistics: 
unpaired two-tailed Student’s t test. ns, not significant; *, p<0.05; **, p<0.01; ***, p<0.001; 
****, p<0.0001. 
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Figure 4.2. Knockdown of p53 promotes cell migration and proliferation.  
(A) Representative random migration tracks of HUVEC treated with control shRNA or p53 
shRNA (p53#19 or p53#20). (B) Migration distance of HUVEC treated with control shRNA or 
p53 shRNA. (C) Migration distance of HUVEC treated with control siRNA or p53 siRNA. (D) 
Density of HUVEC treated with control siRNA or p53 siRNA on indicated days. Statistics: 
unpaired two-tailed Student’s t test (B, C) or two-way ANOVA (D). **, p<0.01; ****, p<0.0001; 
ns, not significant.  
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Figure 4.3. Knockout of p53 does not promote angiogenesis in vivo.  
(A) Representative images of retina from P5 mice with indicated genotypes. (B,C) Sprout 
number/mm in P4 (B) or P5 (C) retina with indicated p53 genotypes. (D,E) Branch number/mm 
in P4 (D) or P5 (E) retina with indicated p53 genotypes. (F,G) Sprouting (F) or branching (G) 
parameter in P5 retina with indicated genotypes. Mice were injected with 0.25 mg/mL tamoxifen 
at P1 and P2. Statistics: unpaired two-tailed Student’s t test. ****, p<0.0001; ns, not significant. 
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CHAPTER V-General Discussion 
A. Summary 
Tumors with a diameter larger than 2 mm require blood vessels to deliver oxygen and 
nutrients for their survival [1], and tumor angiogenesis is considered as a hallmark of cancer [2]. 
Tumor vasculature is phenotypically and functionally abnormal, and recently tumor EC, which 
are an important component of tumor vasculature, were identified with cytogenetic abnormalities 
including aneuploidy, compromised p53 signaling and centrosome over-duplication [3-5], 
indicating that tumor EC possess unstable genetic information, which may contribute to their 
morphological and functional abnormalities. However, it is not entirely clear what are the causes 
and effects of excess centrosomes and abrogated p53 signaling in tumor EC. Previous results 
from our lab demonstrated that excess levels of VEGF-A induce centrosome over-duplication in 
EC [6]. However, it is not clear whether and how other tumor environmental factors contribute to 
centrosome over-duplication. 
Here we show that high levels of BMP2/6/7, hypoxia and loss of p53 promote 
centrosome over-duplication, suggesting that the high percentage of excess centrosomes in tumor 
EC comes from a combination of several signaling inputs. We also show that excess centrosomes 
induce p53-dependent senescence in primary EC. This result indicates that the response to 
centrosome over-duplication is dependent on the transformation status of the cells, and excess 
centrosome-induced senescence contributes to the morphological and functional abnormalities of 
tumor vasculature. In addition, we investigated the potential effects of compromised p53 
signaling in tumor EC, and found that knockdown of p53 contributes to angiogenesis in a cell 
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autonomous manner in vitro. In summary, my work promotes the understanding of centrosome 
over-duplication in tumor EC, and contributes to the study on tumor microenvironment.  
 
B. Tumor-derived factors promote excess centrosomes  
~30% of tumor EC are centrosome over-duplicated [3,5], likely because of the signaling 
input from tumor microenvironment, which is a complex milieu consisted of different cell types, 
growth factors and cytokines [7,8]. Previous studies in our lab demonstrated that high levels of 
VEGF-A induce excess centrosomes in EC, but the frequency of excess centrosomes induced by 
VEGF-A only (<10%) is significantly lower than that in primary tumor EC (~30%) [6]. 
Therefore other environmental/genetic factors may also contribute to centrosome over-
duplication. In Chapter II, I tested the effects of reduced p53 and several tumor environmental 
factors, including high levels of BMP2/6/7, hypoxia and inflammation, on centrosome over-
duplication in EC. 
I found that elevated levels of some BMP ligands, similar to high levels of VEGF and 
FGF ligands, induce excess centrosomes in EC. The mechanisms downstream of these ligands-
induced excess centrosomes are likely very complex, since each of these ligands has multiple 
targets, and can activate several signaling pathways. One potential target is ERK, which VEGF-
A and BMP pathways may share to induce excess centrosomes. Our previous data showed that 
VEGF-mediated effects were ERK-dependent [6], and BMP also up-regulates ERK [9]. 
Therefore it is likely that some of the signaling pathways downstream of VEGF and BMP 
converge to induce excess centrosomes. Alternatively, these two pathways may have some 
different targets, one of which can be SMAD that is correlated with centrosome over-duplication 
status as I showed in Chapter II. Future work will examine the different and/or shared signaling 
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pathways downstream of VEGF-A and BMP. First, although I demonstrated the correlation 
between SMAD phosphorylation and excess centrosomes, it is essential to test whether it is 
required and/or sufficient to drive excess centrosomes. Second interesting question is whether 
ERK is downstream of SMAD in terms of BMP-induced excess centrosomes. Finally, it will be 
interesting to test whether VEGF and BMP can additively or even synergistically promote excess 
centrosomes.  
Tumors are highly vascularized, but in a hypoxic state because tumor blood vessels are 
functionally abnormal [10,11]. Here I show that hypoxia can induce centrosome over-duplication 
in EC, and this is the first study linking cell metabolism with centrosome over-duplication. I also 
demonstrate that hypoxia-induced excess centrosomes in a VEGF-A-independent manner, 
suggesting that there is a cell-autonomous effect of hypoxia on centrosome over-duplication. 
Future studies will focus on understanding the mechanisms of hypoxia-induced centrosome over-
duplication, and several candidates, including Aurora kinase A and miR-210, are potentially 
involved. Aurora kinase A is activated in hypoxia-mimetic conditions [12], and its ectopic 
overexpression leads to centrosome over-duplication [13,14]. Over-expression of miR-210, 
which is a downstream target of hypoxia-inducible factors, also causes centrosome over-
duplication [15]. One will need to express Aurora kinase A siRNA or anti-sense oligonucleotide 
of miR-210 to test their effects on centrosome over-duplication in EC [16]. 
 
C. Excess centrosomes induce p53-dependent senescence 
Results from Chapter II provide several potential mechanisms of excess centrosomes in 
tumor EC. Our previous results demonstrated that excess centrosomes in EC disrupt cell 
migration, polarity and sprouting behavior, indicating that excess centrosomes may account for 
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the morphological and functional abnormalities of tumor vasculature [5,17]. However, 
centrosome is closely associated with cell cycle, and the effects of excess centrosomes on EC 
cycle remain elusive. Interestingly, we observed that isolated tumor EC cannot maintain a high 
percentage of excess centrosomes, indicating a negative impact of excess centrosomes on EC cell 
cycle [5]. Here we show that excess centrosomes activate the tumor suppressor gene p53 in a 
DNA damage-independent manner, and lead to the phosphorylation of p53 at Ser33. Activation 
of p53 further induces senescence, but not apoptosis, in both 2D cultured EC and 3D EC sprouts.  
Before my work, several independent studies with different methods demonstrated cells 
have a p53-dependent surveillance mechanism for loss of centrosomes. By knocking down 
various centrosomal structure proteins, Mikule et al showed that loss of centrosome integrity-
induced p53-dependent cell cycle arrest [18]. A similar study indicates that inhibition of 
centrosome assembly by silencing pericentrin leads to p53-dependent senescence [19]. 
Meanwhile, chemical and genetic inhibition of Plk4, which is required for centrosome 
duplication, activates p53 and induces senescence [20,21]. However, it has been controversial 
whether cells have a surveillance mechanism for centrosome over-duplication. A originally 
proposed p53-dependent “tetraploidy” checkpoint downstream of drug-induced excess 
centrosomes and subsequent cytokinesis failure was later found to be a side effects of drug 
overdose [22,23]. Moreover, cells with excess centrosomes often cluster centrosomes and 
undergo bipolar cell divisions to produce viable progeny [17,24], indicating that in some 
scenarios cells may tolerate centrosome over-duplication and survive. Nevertheless, recent 
evidence suggests that excess centrosomes can induce p53-dependent cell cycle arrest [25,26]. 
Here we use primary human EC to show that excess centrosomes lead to p53 phosphorylation at 
Ser33 and senescence in EC, indicating that EC have a surveillance mechanism for centrosome 
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over-duplication, similar to that for loss of excess centrosomes. Future work will be needed to 
test whether primary cells other than EC have similar surveillance mechanisms for excess 
centrosomes. For example, it is possible that primary epithelial cells also activate p53 upon 
centrosome over-duplication. This hypothesis is consistent with the fact that excess centrosomes 
are linked with a variety of tumors, which presumably lose this checkpoint mechanism during 
tumor development [27]. In addition, I used a tetracycline-inducible system to over-express Plk4 
to induce excess centrosomes as published previously [17]. To generalize my finding, future 
work will need to use other methods to promote excess centrosomes. 
Previous results showed that centrosome over-duplication can cause chromosome 
segregation errors, which induce DNA damage and activate p53[24,28,29]. However, here we 
show that centrosome over-duplication did not induce DNA damage, evidenced by the lack of 
p53 phosphorylation at Ser15 and lack of γH2AX. This finding indicates that DNA damage is 
not the reason for excess centrosome-induced senescence, unlike most conditions such as 
proliferative senescence [30] and oncogenic protein-induced premature senescence [31]. 
Meanwhile and more importantly, the absence of DNA damage suggests that centrosome over-
duplicated cells undergo cell cycle arrest before mitosis, thus avoiding mitotic events that 
potentially lead to chromosome segregation problems. This idea is consistent with the finding 
that mitotic events are not required for loss of centrosome integrity-induced cell cycle arrest [18]. 
Therefore, the surveillance mechanism for centrosome abnormality may exist in interphase. This 
can be advantageous to cells because arresting cells in interphase will significantly reduce the 
possibility of generating tumorigenic mutations. Future work will be needed to test this 
hypothesis. One experiment can be first arresting cells at the beginning of S phase by double 
125 
thymidine block, then inducing the expression of Plk4 and measuring the levels of 
phosphorylated p53 (Ser33) at different time points.  
The mechanisms of excess centrosome-induced p53-dependent senescence remains 
elusive, but several studies provided potential targets, including p38 mitogen-activated protein 
kinase (MAPK) and hippo pathway, to investigate. Loss of centrosome integrity-induced p53 
phosphorylation at Ser33 is dependent on p38 MAPK [18]. In addition, p38 MAPK mediates 
oncogene-induced senescence partially by inducing p53 phosphorylation at Ser33 [32]. 
Therefore it is likely that excess centrosomes also activate p38 MAPK to phosphorylate p53 at 
Ser33, finally leading to EC senescence.  
Evidence suggests that the Hippo pathway is another potentially important mechanism, 
particularly LATS2 which is a serine/threonine kinase mediating Hippo signaling. The core 
Hippo pathway is a kinase cascade, in which MST1/2 (Hpo) phosphorylates Lats1/2 (Wts) that 
further phosphorylates YAP/TAZ (Yki), leading to the cytoplasmic retention or degradation of 
YAP/TAZ [33]. Dephosphorylated YAP/TAZ enters nuclei and promotes gene expression by 
interacting with transcription factors [33]. Evidence suggests that LATS2 may be involved in 
excess centrosome-induced p53-dependent senescence. First, LATS2 localizes at centrosomes 
[34], suggesting LATS2 can directly detect centrosome alterations and initiate downstream 
signaling. In addition, LATS2 is closely involved in cell cycle regulation, and limits centrosome 
over-duplication. Lats2
-/-
 embryos and mouse embryonic fibroblasts display centrosome over-
duplication and genomic perturbations [35], and LATS2 is also phosphorylated by Aurora-A 
kinase [34], which is important for centrosome duplication [13]. Thirdly, LATS2 and p53 are 
associated with each other. LATS2 stabilizes p53 by inhibiting its E3 ligase MDM2, and 
perturbation of centrosome function leads to the translocation of LATS2 from centrosome to 
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nucleus and the accumulation of p53 [36]. Meanwhile, accumulation of p53 promotes LATS2 
expression, creating a positive feedback loop [36]. Furthermore, down-regulation of LATS2 
abrogates oncogenic Ras-induced p53-dependent senescence, indicating an important role of 
LATS2 in senescence [37]. Finally, cytokinesis failure, which leads to excess centrosomes, 
activates LATS2, leading to the stabilization of p53, further suggesting that LATS2 is a mediator 
in excess centrosomes-induced p53-dependent senescence [38]. Based on all previous results, I 
hypothesize that change in centrosome number and/or structure induces LATS2 translocation 
from centrosomes to nucleus, leading to an accumulation of p53 and p53-dependent senescence. 
Future work will be needed to test this hypothesis.  
Another important implication from my study is about the phosphorylation of p53. p53 
have many different post-translational modifications (PTM) that are closely associated with the 
regulation and functions of p53 [39]. For example, the phosphorylation at Ser15 is induced by 
DNA damage, and activates p53-regulated gene expression [40]. Here we show that centrosome 
over-duplication induced p53 phosphorylation at Ser33 but not Ser15, coinciding with 
senescence. Consistent with our results, other studies also linked p53 Ser33 phosphorylation with 
senescence. Loss of centrosome integrity activates p53 phosphorylation at Ser33, and leads to 
senescence [18,19]. In addition, oncogenic Ras induces p53 Ser33 phosphorylation and 
senescence simultaneously [32]. Therefore, p53 Ser33 phosphorylation may be specifically 
associated with senescence. Future experiments are required for testing this relationship. One 
method is to use CRISPR to mutate serine 33 of p53 to alanine, and to detect whether Ser33 is 
required for p53-dependent senescence under several stresses. In parallel, one can generate a 
phospho-mimetic mutant of p53 by mutating serine 33 to aspartic acid, and examine whether this 
mutant is sufficient to induce senescence. Downstream targets of phosphorylated p53 at Ser33 
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need to be identified by biochemical methods and/or bioinformatics to fully understand the 
pathway.  
 
D. A hypothesized model for the development of abnormal tumor vasculature  
My dissertation mainly illustrates the causes and effects of excess centrosomes in EC, 
and found that several environmental factors induce excess centrosomes, which lead to p53-
dependent senescence (Fig. 5.1). Based on previous literature and my dissertation work, here I 
hypothesize a model to explain how tumor vasculature develops and becomes abnormal. Tumors 
that are larger than 2 mm in diameter cannot acquire enough resources for their growth, and 
recruit normal surrounding blood vessels by secreting various angiogenic factors, such as VEGF-
A, bFGF, BMP2/6/7. Normal blood vessels penetrate into tumors, encountering a hypoxic and 
excessive growth factor-filling tumor microenvironment, which induces centrosome over-
duplication in EC. This leads to p53-dependent senescence in tumor EC, serving as a protective 
mechanism to prevent genetic alterations in centrosome over-duplicated tumor EC and to 
maintain tumor blood vessel integrity. However, senescence potentially compromises EC 
functions, leading to a leaky, tortuous and functionally compromised tumor vasculature, and 
aggravating tumor hypoxia. Meanwhile, senescent EC contribute to the inflammation in tumor 
microenvironment, potentially creating a more suitable environment for EC to develop excess 
centrosomes. Through mechanisms that are not completely understood, some senescent EC 
develop p53 mutations/attenuation and maybe other genetic alterations, allowing centrosome 
over-duplicated EC to reinitialize cell cycle and to proliferate. Unfortunately during mitosis, cells 
with excess centrosomes have high potential to form multi-polar spindle or merotelic attachment, 
which results in the accumulation of genetic variations, further contributing to the abnormal 
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structure and function in tumor vasculature. The abrogated p53 signaling also generates a 
selection advantage for tumor EC so that many tumor EC have both centrosome over-duplication 
and abrogated p53 signaling. Together, these effects lead to cytogenetic and phenotypical 
abnormalities in tumor vasculature, and may also help tumor EC develop drug resistance, 
reducing the efficiency of anti-angiogenic therapies. 
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E. Figure 
Figure 5.1. Causes and effects of excess centrosomes in EC 
EC, which line the inner surface of blood vessels, acquire excess centrosomes upon stimulation 
of several environmental factors including high BMP2/6/7, high VEGF and hypoxia. Excess 
centrosomes in EC lead to p53 activation, and finally induce p53-dependent senescence.  
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